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ABSTRACT 
 
Although lung transplantation has become a therapeutic option in treating end-stage lung 
disease, its long-term results in lung transplantation are still modest. The most threatening 
complication after lung transplantation is obliterative bronchiolitis (OB). Histologically, OB 
manifests as epithelial injury, inflammation, fibrosis, and finally obliteration of the small 
airways. The exact pathogenesis of OB is still in part unknown, but it is primarily considered 
a manifestation of chronic allograft rejection. The purpose of this thesis was to further 
elucidate the mechanisms of OB in a heterotopic porcine bronchial transplantation model. The 
focus was on the occurrence of apoptotic cell death in respiratory epithelial injury (I), on the 
role of tumor necrosis factor (TNF-α) (II), of platelet-derived growth factor (PDGF), 
transforming growth factor (TGF-β), and connective tissue growth factor (CTGF) (III) in graft 
inflammation and fibrosis, and of the expression of collagen types I and III (IV).  
 
In a heterotopic porcine bronchial transplantation model, small peripheral bronchi were 
implanted subcutaneously. Bronchial autografts showed preservation of normal histological 
structures, whereas in nonimmunosuppressed allografts, respiratory epithelial damage and 
total bronchial obliteration occurred within three weeks (I-IV). These histopathological 
changes were similar to those observed in human OB.  
 
The apoptotic rate of graft epithelial cells was analyzed by labeling fragmented DNA 
(TUNEL-staining) (I). In nontreated allografts and in allografts with inadequate 
immunosuppression, the apoptotic indexes of the epithelium were high (>1% of the cells 
apoptotic), and increased with progressing epithelial damage preceding bronchial obliteration. 
In allografts receiving effective immunosuppression to prevent alloimmune activation, the 
rate of epithelial apoptosis was similar to that observed in control autografts (<1% of the cells 
apoptotic). These results offer further evidence that the apoptotic death of epithelial cells in 
OB is an important mechanism in events leading to graft deterioration.  
 
Immunohistochemical stainings revealed TNF-α expression in epithelial and inflammatory 
cells, in endothelium, and in fibroblasts (II). TNF-α expression was significantly up-regulated 
in the allografts in comparison to that in autografts. TNF-α inhibition with infliximab, an anti-
TNF-α antibody, reduced inflammation, rate of epithelial loss, fibrosis, and obliteration early 
in OB development. It reduced the numbers of TNF-α-positive epithelial and inflammatory 
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cells and invasion of CD8+ lymphocytes during the first week. This study further confirms 
that TNF-α plays a role in the development of OB by promoting inflammation and epithelial 
injury, and suggests that in lung transplant recipients, inhibition of TNF-α may prove 
beneficial.  
 
PDGF, TGF-β, and CTGF protein expression was analyzed by immunohistochemistry (III). 
Up-regulation of PDGF-A, PDGF receptor α and β, and TGF-β expression occurred in 
bronchial allografts, whereas in autografts and in allografts PDGF-B and CTGF expression 
was similar. This study confirms PDGF and TGF-β as mediators of OB. The protein tyrosine 
kinase inhibitor, imatinib, targeting PDGF receptors, reduced recruitment of inflammatory 
cells and modified expression patterns of PDGF-A and PDGF receptors. This indicates the 
importance of the pathways signaled through PDGF receptors in OB development.  
 
The temporal and spatial activation of type I and III collagen genes was detected by in situ 
hybridization. In nontreated allografts obliterating within 3 weeks, a preponderance of 
fibroblasts showing positivity for collagen III mRNA existed in the obliterative plug and 
bronchial wall. Predominance of fibroblasts expressing collagen III mRNA increased in 
parallel with progressive bronchial wall fibrosis and luminal obliteration. In autografts and in 
allografts with immunosuppression adequate to prevent OB, only a minor degree of collagen 
gene activation occurred without changes in the genetic activity between type I and III 
collagen. These findings suggest a positive association between OB development and type III 
collagen mRNA expression in fibroblasts. 
 
Findings presented in this thesis provide further understanding of the mechanisms of OB and 
offer insights into future development of treatment options.  
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INTRODUCTION 
 
Lung transplantation has become a therapeutic option in treating end-stage lung diseases. The 
first human lung transplantation was reported in 1963 by Hardy et al. Ever since, survival 
rates after lung transplantation have continually improved due to the development of surgical 
and organ-preservation techniques, immunosuppressive regimens, and rejection diagnosis. 
However, the long-term results are still relatively modest; the survival rate 5 years after 
transplantation is 50% (Trulock et al. 2004).  
 
In comparison to other organ transplants, lung transplants are especially susceptible to acute 
and chronic rejection and infection. This feature is a result of the immunologic activity of the 
lung tissue and of its constant exposure to inhaled pathogens. The most life-threatening 
complication after lung transplantation is chronic rejection manifesting as obliterative 
bronchiolitis (OB) (Milne et al. 1992). Clinically, this is called bronchiolitis obliterans 
syndrome (BOS), presenting as airflow obstruction and decrease in lung function capacity 
(Boehler et al. 2003). Its diagnosis is based mainly on exclusion of other possible causes for 
allograft deterioration. Histologically, in OB, inflammation of the small airways occurs, 
leading to epithelial damage and occlusion of the airway lumen (Tazelaar et al. 1994). To 
date, no effective treatment option is available. 
 
The exact pathogenesis of OB is still in part unknown, but the respiratory epithelium is 
considered to be a potential target for immunologic effector mechanisms (Mauck et al. 1996). 
Progressive damage and loss of airway epithelium is accompanied by increased production of 
cytokines and growth factors that augment the inflammatory and fibroproliferative events 
(Hertz et al. 1992, Boehler et al. 1999, El-Gamel et al. 1999, Kallio et al. 1999, Neuringer et 
al. 2000).  
 
The aim of this study was to further explore the mechanisms leading to post-transplant 
obliterative bronchiolitis in a porcine heterotopic bronchial transplantation model. 
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REVIEW OF THE LITERATURE  
 
1. Clinical lung transplantation 
After the first human lung transplantation by Hardy’s team 1963, lung transplantation has 
become a viable treatment option for patients with advanced and end-stage lung disease. 
Single-lung, double-lung, and heart-lung transplantations are performed on both adult and 
pediatric patients. Mainly for children, an option is living-donor lobar lung transplantation. 
According to the registry of the International Society for Heart and Lung Transplantation 
(ISHLT), approximately 1600 adult and 60 pediatric lung transplantations are performed each 
year worldwide (Boucek et al. 2004, Trulock et al. 2004). In Finland, 10 to 15 adult lung 
transplantations are performed annually. Advances in surgical techniques, organ preservation, 
and in rejection diagnosis and treatment, together with improved pre- and postoperative care, 
have contributed considerably to better survival and quality of life (DeMeo et al. 2001a). 
However, that lung allografts are particularly susceptible to infection and acute and chronic 
rejection continues to limit the long-term success of lung transplantation. 
 
1.1 Indications 
The conditions for which lung transplantation is considered a treatment option fall mainly into 
the following categories: septic lung disease (cystic fibrosis, bronchiectasis), restrictive lung 
disease (idiopathic pulmonary fibrosis, other interstitial lung diseases), obstructive lung 
disease (chronic obstructive lung disease, alpha-1-antitrypsin deficiency emphysema), and 
pulmonary vascular disease (primary or secondary pulmonary hypertension) (DeMeo et al. 
2001a). Globally, the four main indications are for chronic obstructive lung disease, 39.0%, 
idiopathic pulmonary fibrosis, 17.0%, cystic fibrosis, 16.0%, and alpha-1-antitrypsin 
deficiency emphysema 9.0% (Trulock et al. 2004). In Finland, the indications are mainly the 
same, with the exception of cystic fibrosis, which in the Finnish population is rare (Salmela et 
al 2004). For obstructive and restrictive lung diseases, single-lung transplantation is the 
commonest treatment option; for septic diseases and pulmonary vascular diseases, double-
lung transplantation is almost exclusively performed. If cardiac failure co-exists, the treatment 
of choice is heart-lung transplantation (DeMeo et al. 2001b). For transplantation, the disease 
process should be symptomatic and progressive despite optimal medical or surgical treatment. 
In patients with end-stage lung disease, the relative contraindications for lung transplantation 
have changed along with improvement in management. The absolute contraindications are 
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concurrent smoking, alcohol or drug abuse, bone-marrow failure, hepatic cirrhosis, active 
malignancy, and HIV infection (DeMeo et al. 2001b). 
 
1.2 Outcome 
Survival rate after lung transplantation according to international registers at the 1-year, 3-
year, and 5-year points are 74%, 58%, and 47% (Trulock et al. 2004). In Finland, this rate is 
69% at 1 year and 46% at 5 years (Salmela et al. 2004). Survival is threatened by 
complications of the lung transplantation procedure itself, infection, and acute, and chronic 
rejection, as well as complications from the immunosuppressive agents. Early complications 
occurring within hours to a few weeks after lung transplantation are: direct complications of 
surgery, airway anastomosis dehishence and stenosis, and ischemia-reperfusion injury 
followed by acute graft dysfunction. Airway stenosis may also occur as a late complication. 
The rate of bacterial, viral, and fungal infections in lung transplant patients in the first two 
months is high and continues to be high compared to rates for other solid-organ recipients. 
Immunosuppressive treatments also leave patients prone to infection and malignancy. 
 
1.3 Immunosuppression 
As in other solid organ transplantation, lung transplant patients need life-long 
immunosuppressive therapy. Therapy should be individualized to effectively prevent allograft 
rejection, but not to subject the patient to a high risk for opportunistic infection and 
malignancy. The most common immunosuppressive drugs and their actions are presented in 
Table 1. 
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Table 1. Common immunosuppressive agents in lung transplantation 
 
Drug Mode of action 
 
Induction  
Anti-lymphocyte globulins  Targets CD3 in T cells. Blocks antigen recognition sites, interrupts signal 
transduction, and stops generation and function of effector cells. 
Anti-thymocyte globulins  Reduces number of effector T cells, and blocks their function. 
IL-2 receptor antagonists 
(daclizumab, basiliximab) 
Target IL-2 receptors on T cells and block their IL-2-dependent activation. 
  Maintenance   
Calcineurin inhibitors   
Cyclosporine A Specific inhibitor of T cell activation: inhibits IL-2 synthesis via calcineurin 
inhibition. 
Tacrolimus Specific inhibitor of T cell activation:  inhibits IL-2 synthesis via 
calcineurin inhibition. 
Purine synthesis inhibitors   
Azathioprine Non-specific inhibitor of proliferating cells, acts by alkylating DNA-
precursors. 
Mycophenolate mofetil Inhibits “de novo” purine synthesis; specifically inhibits proliferation and 
responses of T and B cells. 
Corticosteroids   
Prednisone, prednisolone, methyl 
prednisolone 
Multiple anti-inflammatory and immunomodulatory effects, inhibiting 
arachidonic acid cascade, interfering with macrophage function, and 
inhibiting cytokine transcription and adhesion molecule expression. 
Proliferation signal inhibitors   
Sirolimus 
(rapamycin) 
Inhibits proliferative response of T cells to IL-2 and other cytokines and 
smooth muscle cell (SMC) proliferation. 
Everolimus 
(rapamycin-derivative) 
Inhibits growth factor-stimulated cell-cycle progression of hematopoietic 
and vascular smooth muscle cells via mammalian target of rapamycin 
(mTOR) inhibition. 
 
Preference for induction therapy varies by lung transplant center, and currently is shifting 
from use of anti-thymocyte/lymphocyte globulins to interleukin-2 (IL-2)-receptor antagonists 
(Brock et al. 2001, Trulock et al. 2003). General use of induction therapy is diminishing 
(Trulock et al. 2003). Maintenance immunosuppressive therapy, started intraoperatively, 
includes at the majority of centers a calcineurin inhibitor, purine synthesis antagonist, and 
corticosteroid. The classical triple-therapy combination is cyclosporine (CsA), azathioprine 
(Aza), and methyl prednisolone (MP). Acute rejection usually responds to high-dose steroid 
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treatment or administration of poly- or monoclonal antibody preparations, or to alteration in 
maintenance therapy.  
 
Switching from CsA to tacrolimus and especially from Aza to mycophenolate mofetil (MMF) 
diminishes acute rejection episodes and reverses refractory rejections, and currently 
tacrolimus and MMF are recommended for primary maintenance treatment (Treede et al. 
2001a-b, Izbicki et al. 2002, Vitulo et al. 2002). A common side-effect of calcineurin 
inhibitors is renal impairment, and for these patients a potential alternative drug is sirolimus 
(Snell et al. 2002, Ussetti et al. 2003, Venuta et al. 2004); an increasing number of centers 
include sirolimus in their maintenance regimens (Trulock et al. 2004). However, combined 
with calcineurin inhibitors, sirolimus may promote their nephrotoxic effects, a fact which has 
to be taken into account in using these agents simultaneously.  
 
2. Lung allograft rejection 
Rejection is defined as an immune response that mediates injury and destruction of 
transplanted tissue (Colvin 1990). In clinical transplantation, rejection remains the most 
common cause of graft dysfunction and loss (De Vito Dabbs et al. 2000). Lung allograft 
rejection is divided into three categories: hyperacute, acute, and chronic. 
 
Hyperacute lung allograft rejection develops rapidly, within minutes to hours of engraftment, 
and is caused by pre-formed antibodies against donor major histocompatibility complex 
(MHC) or ABO blood groups (Frost et al. 1996). This complement-mediated injury to graft 
endothelium activates inflammatory and coagulative cascades, thus causing extensive 
thrombosis of graft vessels (Baldwin et al. 1995). Hyperacute rejection is fatal, but fortunately 
very rare. Acute rejection usually occurs within the first months after transplantation, 
although late episodes are frequent (Chakinala et al. 2003). The majority of lung transplant 
patients have at least one acute rejection episode. Chronic rejection occurs in half of lung 
transplant patients within 5 years (Estenne et al. 2002, Trulock et al. 2004), being the most 
common cause of late graft failure. Both acute and chronic rejection of the lung are classified 
and graded according to the ISHLT working formulation (Yousem et al. 1996). Table 2 
summarizes the grading of rejection and the main histopathological features. Signs of acute 
and chronic rejection may exist concomitantly. Chronic vascular rejection probably 
contributes less to chronic allograft dysfunction in the lung than in other solid organ 
transplantation (Radio et al. 1996). The gold standard in rejection diagnosis is biopsy 
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(Higenbottam et al. 1988, Yousem et al. 1996), and specimens may be obtained either trans- 
or endobronchially, or rarely, in open lung biopsy. Target areas for biopsies may be identified 
by computed tomography (CT) (Ikonen et al. 1996, 1997). Other diagnostic tools such as 
bronchoalveolar lavage (BAL) samples and lung function tests may be additionally employed. 
 
Table 2. Grading and histological features of lung allograft rejection 
 
Grade  Histological features 
0 - none 
      1 - minimal 
2 - mild 
Normal pulmonary parenchyma without evidence of 
mononuclear infiltration or of alveolar hemorrhage. 
 
 
Infrequent (A1) or frequent (A2) perivascular 
cuffing of venules and arterioles by predomonantly 
small mature lymphocytes, occasional plasma cells, 
macrophages, and neutrophils.   
 
        3 - moderate 
Inflammatory cell infiltrate extending out to 
alveolar septae and airspaces, expansion of alveolar 
septae. Lymphocytes, neuthrophils, and eosinophils 
common.  
A 
Acute rejection                    
(all with or without Grades B, C, D) 
   4 - severe 
Inflammatory process becoming more diffuse with 
parenchymal necrosis, hemorrhage, and hyaline- 
membrane formation. 
    0 - absent 
 
Grade B 
Lymphocytic 
bronchitis/bronchiolitis 
1 - 4 present 
(minimal to 
severe) 
Inflammatory cell infiltrates cuffing small vessels in 
the submucosa and adventitia of airways. May occur 
in the presence or absence of perivascular infiltrates. 
          0 - absent 
 
 
      1 – present 
Submucosal and intraluminal scarring of 
membranous and terminal bronchioles.  Initially, 
perhaps loose myxoid granulation tissue with 
variable numbers of inflammatory cells. At later 
phase, eccentric, confluent dense hyalinized 
collagen plaques. 
a - active 
 
Fibrosis present with intra- and/or peribronchial 
mononuclear cell infiltrate. 
Grade C 
Chronic airway rejection-     
obliterative bronchiolitis 
b - inactive 
Bronchial scarring without inflammatory 
component 
0 - absent 
Grade D 
Chronic vascular rejection –
accelerated graft vascular sclerosis 1 - present 
Patchy atherosclerosis involving arteries and veins. 
Circumferential intimal proliferation of 
myofibroblasts and smooth muscle cells. With 
extensive disease, internal elastica may become 
fragmented with thinning of underlying muscular 
wall. 
 
Data based on the Revised ISHLT working formulation for classification and grading of lung allograft rejection 
by Yousem et al. 1996, and on Tazelaar et al. 1994 and Wallace et al. 2003.  
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2.1 Obliterative bronchiolitis (OB) 
The main limitation on long-term survival after lung transplantation is OB, a condition first 
described in 1984 by Burke et al. The pathogenesis of OB is still uncertain, although it is 
considered a manifestation of chronic rejection (Yousem et al. 1990, Milne et al. 1992, 
Sakiyama et al. 1994). Many factors may predispose to its development (Table 3). 
 
Table 3. Risk factors for OB 
 
Probable Potential 
Acute rejection CMV infection (without 
pneumonitis) 
Donor-specific reactivity in primed 
lymphocyte tests 
Lymphocytic bronchiolitis Long graft-ischemic time Recipient and donor characteristics 
Cytomegalovirus (CMV) 
pneumonitis 
HLA-mismatching Gastroesophageal reflux with 
aspiration 
 Bacterial/fungal/non-CMV viral 
infection 
 
Data modified from Estenne et al. 2002 and Sharples et al. 2002. 
 
The prevailing hypothesis is that an alloreactive immune response is central in OB in 
initiating the irreversible changes (Milne et al. 1992, Duncan et al. 1996, Heng et al. 1998, 
Maasilta et al. 2001, Sharples et al. 2002). However, allograft-independent factors such as 
ischemia-reperfusion injury, infections, and gastroesophageal reflux with aspiration may also 
contribute to progressive injury of the graft (Keenan et al. 1991, Tullius et al. 1995, Fiser et 
al. 2002, Vilchez et al. 2003, Cantu et al. 2004).  
 
Histologically, OB manifests as epithelial injury, inflammation, fibrosis, and finally, as 
obliteration of the small airways (Tazelaar et al. 1994). The disease process begins with a 
peribronchiolar leukocyte infiltration that invades the basement membrane, submucosa, and 
luminal epithelium. Subsequently, mesenchymal cell proliferation, extracellular matrix 
deposition, and granulation tissue formation occur around the lumen of the bronchioli. 
Ultimately, fibroblasts and mature collagen obliterate the airway (Paradis et al. 1993, Kelly et 
al. 1997).  
 
2.2 Clinical manifestation and diagnosis of OB  
Clinically, OB manifests as decline in respiratory function. The term bronchiolitis obliterans 
syndrome (BOS) connotes graft deterioration secondary to progressive airway disease with no 
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other cause (Cooper et al. 1993). Infections, acute rejection, bronchial hyperresponsiveness, 
and anastomotic complications can confound the diagnosis and should be excluded. BOS 
stage 1 is diagnosed by a 66 to 80% decline in forced expiratory volume in one second 
(FEV1), but an earlier, potential-BOS stage is considered as a 10% to 19% decrease in FEV1 
(Estenne et al. 2002).  BAL fluid may show neutrophilia and elevated levels of several 
inflammatory mediators (Tiroke et al. 1999, Slebos et al. 2002). Transbronchial biopsy 
sampling is insensitive and difficult because of the patchy distribution of OB lesions (Estenne 
et al. 2002) and, actually, the designation of BOS does require no histological confirmation. 
The term OB means a histologically proven diagnosis. The histologic activity of OB does not 
always reflect the clinical activity monitored by pulmonary function tests, however. In long-
term follow-up of lung transplant patients, repeated CT scanning is a sensitive and specific 
method of diagnosing BOS (Ikonen et al. 1996). CT images of BOS patients reveal air 
trapping, peripheral bronchial narrowing, central bronchial dilatation, and changes in 
peripherial vasculature, hyperlucency, and mosaic phenomen (Ikonen et al. 1996, Lee et al. 
2000). 
 
3.  Immunological basis of OB 
Alloreactive T cells are requisite mediators of the alloimmune response (Bolton et al. 1987, 
Bolton et al. 1989). Antigens provided by the allograft trigger the activation and proliferation 
of these cells. As a consequence, effector elements are generated that mediate graft injury and 
are responsible for the clinical manifestations of allograft rejection.  
 
3.1 Alloantigens  
Organ donors and recipients usually differ at several genetic loci, some of which the 
recipient’s immune system may recognize as foreign. The most important determinant in 
transplantation immunology is the major histocompatibility complex (MHC) (Bach et al. 
1976, Gaston et al. 1995). The MCH consists of class I and II proteins, which present antigen 
to T cells in the form of peptides. The principal products of human MCH, the human 
lymphocyte antigen (HLA) complex, are the class I molecules HLA-A, -B, and –C, and the 
class II molecules DR, DQ, and DP. Some studies have proposed an association between OB 
and an HLA mismatch (Harjula et al. 1987, Hosenpud et al. 1996, Chalermskulrat et al. 
2003b). This risk may be mediated through an increased rate of acute rejection (Heng et al. 
1998). 
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MHC class I proteins are expressed on most cell types, and abundantly in endothelial cells 
and leucocytes. Class II protein expression is restricted to B cells, macrophages, dendritic 
cells, and endothelial cells (Daar et al. 1984, Page et al. 1992). Interferon-γ (IFN-γ) and other 
cytokines can also induce other cell types to express class II molecules (Pober et al. 1986, 
Auchincloss Jr. 1995, Mauck et al. 1996). Patients with OB have shown enhanced expression 
of class II molecules in bronchial epithelial cells (Taylor et al. 1989). It is also suggested that 
the transplantation procedure may break the tolerance to autoantigens (Fedoseyeva et al. 
1999), such as the collagen V in lung tissue (Mares et al. 2000, Haque et al. 2002) that may 
subsequently generate an immune response.   
 
3.2 Allorecognition 
Recipient T cells are capable of recognizing donor antigens on donor cells (direct pathway) or 
donor antigens processed and presented by the recipient’s own MHC molecules (indirect 
pathway) (Shoskes et al. 1994, Auchincloss et al. 1996, Rogers et al. 2001). Both CD4+ 
(helper) and CD8+ (cytotoxic) T cells are primed to allorecognize by direct and indirect 
pathways (Heeger 2003). Cells presenting peptides in MHC molecules are called antigen-
presenting cells (APC). These cells consist mainly of dendritic cells and monocyte-
macrophages, but other cells may also act as APC. Classically, CD8+ T cells act with class I 
molecules presenting intracellular foreign antigens, while CD4+ T cells act with extracellular 
antigens in class II molecules. Cross-reactivity to class I and II MHC molecules may, 
however, occur (Auchincloss et al. 1996), and MHC class I may also present extracellular 
antigens to indirectly primed recipient CD8+ T cells (Yewdell et al. 1999). CD4+ 
alloreactivity to both donor HLA class I and class II molecules in OB is believed to be 
important (Lu et al. 2003).  
 
T cells that are directly primed may mediate rejection early post-transplantation, and this 
pathway would thus be involved in acute rejection (Baker et al. 2001, Saiki et al. 2001). Over 
time, donor antigen-presenting cells are destroyed, and in chronic rejection a shift occurs 
towards the indirect recognition (Vella et al. 1997, Baker et al. 2001). A correlation exists 
between OB in patients and indirect recognition of donor mismatched class I and II molecules 
(Sivasai et al. 1999, Reznik et al. 2001). In experimental OB, however, both indirect and 
direct allorecognition patterns can cause obliterative changes (Chalermskulrat et al. 2003a, 
Richards et al. 2003).  
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3.3 T cell activation  
T cells react to donor antigens through T cell receptors (TCR).  To fully activate alloreactive 
T cells, a second or co-stimulatory signal between the APC and T cell is required after 
recognition of an antigen. The lack of these signals renders T cells unresponsive to further 
antigenic stimulation (Schwartz 1990). The co-stimulatory signal may be additional cell-cell 
interaction through cell surface molecules or be a stimulus by various cytokines, like TNF-α 
(Joseph et al. 1998). Important co-stimulatory pathways are CD28-B7 (Linsley et al. 1993, 
Sayegh et al. 1998) and CD40-CD145 (CD40 ligand) (Sho et al. 2002, Yamada et al. 2002) 
interactions. After ligation of the TCR with antigens presented by APC, CD28 on T cells 
binds the B7 molecules on APC. Inhibition of the CD28/B7-2 co-stimulatory pathway delays 
development of experimental OB and reduces proinflammatory cytokine responses (Tikkanen 
et al. 2002).  
 
3.4 T cell responses  
Following activation of an immune response, T cells produce cytokines and growth factors 
and stimulate other mediator cells. To maintain the rejection response, communication is 
required between infiltrating leucocytes, endothelium, parenchymal cells, and extracellular 
matrix. These events are mediated through generation of adhesion molecules, chemokines, 
and cytokines (Rocha et al. 2003).  
 
T helper cells are considered crucial in initiating the organ rejection process. These cells are 
mainly CD4+ cells, but CD8+ T cells may also act as T helper cells. T helper cells produce 
cytokines that drive the immune response towards a cell-mediated response (Th1 pattern), or 
towards an antibody-dominated response (Th2 pattern). Polarization of T helper cells into 
either Th1 or Th2 types is influenced by various factors, including the nature and strength of 
antigenic stimuli, the type of antigen-presenting cells, the site of the response, and the 
cytokine milieu (Shirwan 1999, Le Moine et al. 2002). In the direct presentation, T cells 
encounter APCs that present high levels of allopeptides, resulting in differentiation into Th1 
cells (Illigens et al. 2002). In the indirect presentation, only limited amounts of allopeptides 
are presented to T cells, resulting in Th 2 differentiation (Constant et al. 1995).   
 
Multiple studies have suggested that the Th1 type alloimmune response mediates the OB 
pathogenesis (Sundaresan et al. 1995, Koskinen et al. 1997, Boehler et al. 1999, Gu et al. 
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2000, Tikkanen, et al. 2002), although chronic rejection in general is more closely associated 
with Th2 responses (Shirwan 1999). Cytokines mediating the Th2 responses are IL-4, IL-5, 
and IL-10 (Strom et al. 1996, Joosten et al. 2003). Overexpression of Th1 cytokines such as 
IL-1, IL-2, IL-8, IFN-γ, and TNF-α have all been implicated in OB development (Sundaresan 
et al. 1995, Koskinen et al. 1997, Gu et al. 2000, Neuringer et al. 2000, Scholma et al. 2000, 
Smith et al. 2001, Tikkanen et al. 2002). The Th2 type cytokines IL-4, IL-6, and IL-10 
(Neuringer et al. 2000, Scholma et al. 2000) are also involved, suggesting that multiple T cell 
pathways contribute to OB development. 
 
3.5 Adhesion molecules and chemokines 
The process of leucocyte extravasation involves sequential adhesive interactions between the 
leucocyte and endothelium. The complex process of recruitment, activation, adhesion, and 
migration of leucocytes is coordinated by adhesion molecules and chemokines (Butcher et al. 
1999). These molecules also play a role in antigen presentation. Their expression is 
upregulated by proinflammatory cytokines, with different effects from distinct cytokine 
patterns (Collins et al. 1995). 
 
The adhesion molecules are traditionally divided into three categories: selectins, integrins, 
and the immunoglobulin superfamily. In terms of chronic lung rejection, upregulation of 
multiple adhesion molecules precedes OB in biopsy specimens (Devouassoux et al. 2001), 
and overexpression of E-selectin (endothelial-leucocyte adhesion molecule, ELAM-1) 
correlates with OB (Shreeniwas et al. 1996). In addition, the intercellular adhesion molecule-1 
(ICAM-1) is present in biopsies and in BAL fluid, but with no direct correlation with OB 
(Milne et al. 1994, Shreeniwas et al. 1996, Reynaud-Gaubert et al. 2002). In murine tracheal 
allografts, however, brief treatment with an antibody against leukocyte function-associated 
antigen-1 (LFA-1), a ligand of ICAM, leads to prolonged OB inhibition (Morikawa et al. 
2001). In experimental OB, at the time of maximal cellular rejection, ELAM-1 expression is 
upregulated (Maasilta et al. 2001). Blocking selectin-based cell adhesion significantly reduces 
allograft rejection in rat lung transplantation (Brandt et al. 1997), supporting the association 
between OB and increased expression of ELAM-1. Recently, detection of increased 
expression of integrin αVβ6 in healing rat tracheal isografts (Dosanjh et al. 2004), has 
suggested a role for this molecule in cell-cell interactions in graft re-epithelialization. 
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The chemokine superfamily is divided into four subfamilies (C, CC, CXC, and CX3C). C and 
CXC chemokines attract lymphocytes, while CC chemokines predominantly recruit 
mononuclear cells (Baggiolini et al. 1997). In OB, the role of several chemokines has been 
characterized. BAL fluid of OB patients shows increased levels of monocyte chemoattractant 
protein-1 (MCP-1) (Reynaud-Gaubert et al. 2002), CXCL8 (Riise et al. 1999, Elssner et al. 
2000), CCR2 (Belperio et al. 2001), CXCL9, CXCL10, CXCL11, and CXCR3 (Agostini et al. 
2001, Belperio et al. 2002). Broad-spectrum chemokine inhibition reduces inflammation and 
attenuates epithelial injury and luminal obliteration (Naidu et al. 2003). A similar effect is 
evident with inhibition of CCL5 chemokine (Farivar et al. 2003). 
 
3.6 Macrophages  
In chronic allograft rejection, tissue macrophages are important effector cells. They 
phagocytose foreign antigens and present them to T cells (Shirwan 1999). Macrophages 
interact with T cells in generating an alloimmune response, and Th1 type cytokines are strong 
stimulators of macrophages (Romagnani 1999). In transplanted human and animal lungs, 
alveolar macrophages secrete inflammatory mediators, chemoattractants, and growth factors 
(Hertz et al. 1992, Fattal-German et al. 1996, Magnan et al. 1996, Sekine et al. 1997, Fattal-
German et al. 1998, Rizzo et al. 2000). These mediators stimulate endothelial and epithelial 
cells, leucocytes, and fibroblasts to express adhesion molecules and release cytokines and 
growth factors to facilitate cell recruitment and proliferation. In experimental OB, 
macrophages infiltrate into tissue (Neuringer et al. 1998, Maasilta et al. 2001). In BOS 
patients’ biopsy samples, higher amounts of tissue macrophages are evident than in stable 
recipients (Leonard et al. 2000). 
 
3.7 B cells and humoral immunity  
In chronic allograft rejection, B cells produce antibodies directed against MCH class I and II 
antigens, and non-MHC antigens. B cells recognize antigen through their cell-surface antigen 
receptors. Activation of antigen receptor with co-stimulatory signals from T cells or cytokines 
results into B cells’ differentiation into plasma cells that secrete large amounts of antibody. In 
lung transplant recipients, the presence of antibodies against HLA indicates higher risk for 
OB (Jaramillo et al. 1999, McKenna et al. 2000, Reznik et al. 2000, Palmer et al. 2002). Anti-
HLA antibodies may be the cause of epithelial cell damage and thus contribute to 
development of OB (Reznik et al. 2000, Jaramillo et al. 2003). Moreover, non-HLA 
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antibodies against airway epithelial cells have also been detected in OB patients (Jaramillo et 
al. 2001). 
 
Activation of the complement cascade results in recruitment and activation of neutrophils and 
macrophages as well as amplification of the immune response. Deposition of complement 
into alveolar tissue and in capillaries may occur (Magro et al. 2002). In experimental OB, 
inhibition of complement leads to reduced graft inflammation and fibrosis (Kallio et al. 2000). 
 
3.8 Other immune cells in OB 
Because neutrophils clear invading micro-organisms, they are important for the innate 
immune system. They are recruited and activated by macrophage- and lymphocyte-derived 
proinflammatory mediators. Neutrophils generate and release reactive oxygen species and 
several proteases (Sibille et al. 1990, Chabot et al. 1998). When activated in the transplanted 
lungs, neutrophils can cause significant lung damage (Elssner et al. 2001). Elevated numbers 
of neutrophils within the airways of OB patients is a general feature, and in OB is considered 
to be one diagnostic hallmark (DiGiovine et al. 1996, Elssner et al. 2000, Reynaud-Gaubert et 
al. 2000, Zheng et al. 2000). Lungs of BOS patients show impaired antiprotease defense 
mechanisms and increased oxidant activity (Riise et al. 1998, Hirsch et al. 1999, Behr et al. 
2000).  
 
Cytotoxic natural killer (NK) cells are also part of the innate immunity, and in lung transplant 
recipients, increased levels of NK cells can appear in BAL fluid (Crim et al. 1996, Ward et al. 
2001). In canine lung transplantation, these cells were found to be elevated in peripheral 
blood (Nguyen et al. 1993). Eosinophils are associated with allergies, hypersensitivity 
reactions, and asthma (Allen et al. 1994), and are capable of producing cytotoxic proteins. 
Tissue and BAL fluid eosinophils are associated with aggressive acute rejection of the lung, a 
relationship, however, not clearly defined (Riise et al. 1996, Dosanjh et al. 1997, Dosanjh et 
al. 1998, Bewig et al. 1999, Mogayzel Jr. et al. 2001). Mast cells produce and store cytokines, 
vasoactive agents, growth factors, and enzymes (Wershil et al. 1988, Roberts et al. 2000) and 
degranulate upon stimulation. In postmortem samples of patients with OB, numbers of mast 
cells are significantly increased (Yousem 1997). 
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4. Mechanisms in OB 
In pathogenesis of OB, alloimmune-induced inflammatory cell invasion, epithelial injury, 
fibroblast proliferation, extracellular matrix deposition, and finally obliteration of the 
bronchiolar lumen are the key events. These events are suggested to occur or to be mediated 
by various mechanisms.  
 
4.1 Apoptosis  
One of the mechanisms of cellular death is apoptosis, an energy-dependent active process that 
is genetically regulated (Steller 1995). It is a physiological phenomenon necessary to tissue 
homeostasis, but defects in its regulation may cause numerous diseases. In apoptotic cell 
death, the cell shrinks, plasma membrane undergo blebbing, mitochondria release cytochrome 
c, and the DNA fragments. Ultimately, the cell breaks into small apoptotic bodies which are 
cleared through phagocytosis by neighboring cells (Delhalle et al. 2003). In cells undergoing 
apoptosis, the plasma membrane structure is conserved throughout the process, minimizing 
the damage to neighboring cells. This is in contrast to necrotic cell death, characterized by 
cellular swelling, disruption of the plasma membrane, and leakage of intracellular contents 
(Assuncao Guimaraes et al. 2004).   
 
Apoptosis is a strictly regulated process in which several steps are controlled by various 
families of proteins. The morphologic changes are initiated by the activation of proteases 
called caspases. These exist in cells as inactive zymogens, and require proteolytic cleavage for 
their activation (Salvesen et al. 1997). Many pathways for activating caspases exist, but two 
of the most investigated are the extrinsic (death receptor) and the intrinsic (mitochondrial) 
pathway (Reed 2000). The extrinsic pathway is triggered by activation of TNF receptor 
superfamily members (Wang et al. 2003). These include the TNF-α/TNF receptor and Fas/Fas 
ligand (FasL) interactions (Locksley et al. 2001). The intrinsic pathway is triggered by 
mitochondrial release of various molecules (e.g., cytochrome c) in response to intracellular 
injuries like DNA damage. The caspase activity is modulated by several pro- and 
antiapoptotic proteins (e.g., the Bcl-2 family of proteins, inhibitors of apoptosis proteins) 
(Delhalle et al. 2003).  
 
In transplant rejection, apoptosis is suggested to be one of the mechanisms of cellular loss 
(Kabelitz et al. 1998). Alloreactive T cells may induce apoptosis of the target cells by 
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releasing perforin and granzyme B, and cytotoxic cytokines like TNF-α and INF-γ. Cytotoxic 
T cells may also bear the FasL, a transmembrane protein which induces apoptosis after 
binding to Fas protein on target cells (Kroemer et al 1995, Nagata 1999, Ross et al. 1999, 
Zavazava et al. 2000).  
 
In acute and chronic liver, kidney, and heart allograft rejection, apoptotic epithelial and 
parenchymal cell death may contribute to graft deterioration (Krams et al. 1995, Ito et al. 
1995, Laguens et al. 1996, Szabolcs et al. 1996, Laine et al. 1997). In the context of lung 
transplantation, apoptotic cell death has been investigated in ischemia-reperfusion injury, and 
in acute and in chronic lung allograft rejection, both in human samples and in rodent models 
(Hansen et al. 1999, Hansen et al. 2000, Fischer et al. 2000, Keshavjee et al. 2000, Schmid et 
al. 2000, Stammberger et al. 2000, Neuringer et al. 2002). Ischemia-reperfusion injury 
enhances apoptotic activity (Fischer et al. 2000a-b, Keshavjee et al. 2000, Stammberger et al. 
2000), and in acute lung rejection the number of apoptotic cells correlates with rejection grade 
(Hansen et al. 1999). In the lungs of OB patients, increased apoptotic activity occurs (Hansen 
et al. 2000), meaning that apoptotic cell death may contribute to the disease process. 
 
4.2 TNF-α 
Currently, the TNF superfamily comprises at least 18 distinct members with numerous effects 
on cell proliferation, survival, and apoptosis (Gaur et al. 2003). TNF-α is a pleiotropic 
cytokine with strong proinflammatory and immunomodulatory properties as well as 
fibrogenic effects (Beutler et al. 1988, Strieter et al. 1996). It is involved in the development 
of cytotoxic lymphocytes, in enhancing T-cell responses, and in regulating leukocyte 
movement. It also shows direct cytotoxic activity (Scheurich et al. 1987, Sedgwick et al. 
2000, Aspalter et al 2003). TNF-α induces the release of other inflammatory mediators and of 
angiogenic factors and chemokines. Adhesion molecule expression in endothelial cells is up-
regulated by TNF-α, enabling leukocyte extravasation. TNF-α also promotes fibroblast 
proliferation and chemotaxis (Miyazaki 1995, Strieter et al. 1996, Chou et al. 1996, Zhang et 
al. 1997, Eidelman et al. 2001). TNF-α exists in tissues either as a soluble or as a membrane- 
bound form and exerts its effects through two specific cell-surface receptors, TNF-R1 and 
TNF-R2 (Bazzoni et al. 1996, MacEwan 2002). In the lung, epithelial and endothelial cells, 
alveolar macrophages, and mesenchymal cells are capable of producing TNF-α (Fattal-
German et al. 1996, Ermert et al. 2003, Shinbori et al. 2004).  
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TNF-α plays a critical role in many acute and chronic inflammatory diseases (Holtmann et al. 
2004). In lung allograft rejection, TNF-α is suggested to contribute both to acute and to 
chronic forms (Saito et al. 1993, DeMeester et al. 1993, Magnan et al. 1994, Sekine et al. 
1997, Smith et al. 2001, Aris et al. 2002). Additionally, TNF-α overexpression is detectable in 
chronic rejection of human hearts (Hsu et al. 2003, Ueland et al. 2003) and in chronic kidney 
(Hancock et al. 1993, Azuma et al. 1995, Song et al. 2002) and liver rejection (Martelius et al. 
1999, Evans et al. 2001). 
 
Studies in rodent models of OB reveal that TNF-α inhibition attenuates acute (Saito et al. 
1993, DeMeester et al. 1993) and chronic rejection (Smith et al. 2001, Aris et al. 2002). 
Clinically, blockade of the proinflammatory effects of TNF-α by either anti-TNF-α 
antibodies or soluble TNF-α receptor fusion protein has significantly changed the therapy for 
diseases with chronic inflammation as a key feature in their pathophysiology (Feldman et al. 
2001, Suryaprasad et al. 2003, Rutgeerts et al. 2004).  
 
4.2.1 Infliximab 
 
Infliximab is a chimeric human mouse monoclonal antibody targeting both soluble and 
membrane-bound forms of TNF-α (Scallon et al. 1995, Valle et al. 2001). Currently, it is 
approved as a therapy for refractory cases of rheumatoid arthritis and inflammatory bowel 
diseases (Lipsky et al. 2000, Rutgeerts et al. 2004). In lung diseases, infliximab therapy has 
been successful in individual cases of rheumatoid arthritis-associated pulmonary fibrosis 
(Vassallo et al. 2002) and in sarcoidosis (Baughmann et al. 2003). Infliximab is suggested to 
have potential in the treatment of organ allograft rejection (Feldman et al. 1998). In two 
intestinal transplant patients, reversal of refractory acute cellular rejection occurred after 
infliximab treatment (Pascher et al. 2003), and in renal transplantation, single-center trials are 
ongoing (Vincenti 2003). 
 
4.3 PDGF, TGF-β, and CTGF  
PDGF, TGF-β, and CTGF are peptide growth factors that regulate and participate in multiple 
molecular and cellular events, including inflammatory and fibroproliferative processes 
(Heldin et al. 1999, Ihn 2002, Brigstock 2003). The PDGF family consists of five different 
dimers built up of four different polypeptide chains. These chains can form disulfide-bonded 
 24
hetero- or homodimers consisting of PDGF-AA, PDGF-BB, PDGF-AB (Heldin et al. 1999), 
and the novel members PDGF-CC and PDGF-DD (Li et al. 2000, Bergsten et al. 2001, Heldin 
et al. 2002). PDGF ligands act via two receptor tyrosine kinases: PDGF receptors (PDGFR) α 
and β (Heldin et al. 1999). PDGF-AA ligand binds only to an α-α receptor dimer, PDGF-AB 
binds to α-α and α-β receptors, and PDGF-BB can bind to α-α, α-β, and β-β receptors. PDGF-
CC binds to α-α receptors, and PDGF-DD to β-β receptors (Bergsten et al. 2001, Heldin et al. 
2002).  
 
In mammalians, three isoforms of TGF-β exist; TGF-β1, TGF-β2, and TGF-β3 (Kingsley 
1994). In addition, the TGF-β superfamily comprises many other factors, each playing a role 
in tissue differentiation and morphogenesis. Of the isoforms, TGF-β1 is the most ubiquitious 
in all tissues. TGF-β signal transduction is initiated by binding of two cell-membrane serine-
threonine kinase receptors, termed TGF-β receptor type I and II. In addition, a type III 
receptor exists that is suggested to function as a reservoir of TGF-β (Derynck et al. 1997).  
 
CTGF belongs to the connective tissue growth factor/cysteine-rich 61/nephroblastoma 
overexpressed (CCN) protein family (Brigstock 2003). CTGF’s mode of action is mediated 
by integrins, e.g., αvβ3, αIIbβ3, αMβ2, identified as its cellular receptors (Babic et al. 1999, 
Jedsadayanmata et al. 1999, Schober et al. 2002). The cellular sources PDGF, TGF-β, and 
CTGF, their biological responses, and observations in organ transplants are summarized in 
Table 4. 
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 Table 4. Cellular sources of PDGF, TGF-β, and CTGF in the lung, their biological response, and 
appearance in organ transplants 
 
Growth 
factor Cellular sources 
 
Biological response 
 
In organ transplants (clinical 
and experimental) 
PDGF 
Acts as mitogen for connective tissue 
cells 
 
Induces adhesion molecule expression 
 
Stimulates chemotaxis of macrophages, 
smooth muscle cells, and fibroblasts 
 
Induces growth factor and cytokine 
release from macrophages and T cells 
 
Promotes angiogenesis 
 
Induced in acute and 
chronic kidney rejection 
(Fellström et al. 1989 
Alpers et al. 1996, Floege et 
al. 1998, Savikko et al. 2001 
and 2003), in liver rejection 
(Hayashi et al. 1995), in 
heart graft acute rejection 
(de Groot-Kruseman et al. 
2003, Sack et al. 2004) and 
arteriosclerosis (Mancini et 
al. 2000, Sihvola et al. 1999 
and 2003), and in chronic 
lung rejection (Hertz et al. 
1992, Hirabayashi et al 
1996, Kallio et al. 1999, 
Aris et al. 2002). 
 
TGF-β 
Acts as chemoattractant and stimulator 
for connective tissue cells 
 
Elevates production of extracellular      
matrix 
 
Up-regulates integrins, enhances cell 
adhesion 
 
Has stimulatory, but also inhibitory 
effects on inflammatory cell 
proliferation  
 
Promotes angiogenesis 
 
Overexpression attenuates 
acute heart and lung 
rejection (Qin et al. 1994, 
Mora et al. 2000). 
 
Associated with increased 
fibrosis in chronic liver 
(Demirci et al. 1996), 
kidney (Shihab et al. 1995), 
heart, (Aziz et al. 2000), and 
lung (El-Gamel et al. 1998 
and 1999, Charpin et al. 
1998, Ramirez et al. 2004) 
rejection.  
 
CTGF 
Endothelial cells, macro-
phages, epithelial cells, 
fibroblasts, platelets, 
smooth muscle cells, 
lymphocytes, neutrophils 
(TGF-β), and 
chondrocytes (CTGF) 
 
Promotes fibroblast proliferation and 
migration, cellular adhesion, and 
extracellular matrix formation, and 
angiogenesis 
 
Expressed in a mouse model 
of chronic lung rejection 
(Ramirez et al. 2004). 
Data based on Wiedmeir et al. 1994, Heldin et al. 1999, Pan et al. 2001, Blom et al 2002, Ihn 2002, Atamas et al. 
2003, Black et al. 2003, Workalemahu et al. 2003, and Bartram et al. 2004. Experimental studies in italics. 
 
In lung-transplant patients with OB, levels of PDGF and TGF-β have appeared as elevated in 
BAL fluid or in transbronchial biopsies (Hertz et al. 1992, El-Gamel et al. 1999). In rodent 
models of OB, expression of PDGF and TGF-β is also elevated (Kallio et al. 1999, Aris et al. 
2002). Daily injections of PDGF induce fibroproliferation (Al-Dossari et al. 1995), whereas 
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inhibition of PDGF receptor slows development of OB (Kallio et al. 1999, Tikkanen et al. 
2003). CTGF contributes to various lung diseases (Allen et al. 1999, Moussad et al. 2000, 
Atamas et al. 2003, Ning et al. 2004), but in the context of lung transplantation, only one 
study exists. Recently, CTGF was detected in mouse tracheal allografts (Ramirez et al. 2004).  
 
4.3.1 Imatinib 
 
Of the agents capable of interrupting growth factor signaling, imatinib mesylate (STI571) is a 
protein tyrosine kinase inhibitor currently used in clinical oncology (George 2003). It acts on 
signal transduction of the PDGF receptors (Buchdunger et al. 2000, Apperley et al. 2002) and 
additionally inhibits the binding site of stem cell receptor c-Kit, and tyrosine kinases V-Abl 
and ARG (Heinrich et al. 2000, Druker et al. 2001, Okuda et al. 2001). In experimental organ 
transplantation, imatinib has shown promise in preventing chronic rejection in rodent kidney, 
heart, and aorta transplantation models (Savikko et al. 2003, Sihvola et al. 2003). 
 
4.4 Collagen I and III 
Collagens, the major constituents of connective tissue (Byers 2000), play a crucial role in 
maintaining the structural integrity of many tissues and organs. Additionally, collagens 
participate in numerous other biological functions, e.g., in cell attachment, chemotaxis, 
platelet aggregation, and filtration through basement membrane (Midwood et al. 2004). Lung 
extracellular matrix consists mainly of interstitial collagens type I and III (Kirk et al. 1984). 
Fibroblasts are the major synthetizers of type I and III collagens in the lung; however, but 
endothelial, epithelial, alveolar type II, and smooth muscle cells also produce these collagens 
(McAnulty et al. 1995). Type I collagen exists as a heterotrimer composed of two different α-
chains [α1(I)]2α2(I), and type III collagen as a homotrimer of three identical α-chains 
[α1(III)]3 (Linsenmayer 1991). Collagen gene regulation is a complex interplay between 
upregulatory factors and extracellular matrix-degradating proteins and their tissue inhibitors 
(Ghosh 2002, Pardo et al. 2002). Imbalance between synthesis and degradation of collagen 
characterizes fibrotic disorders (Myllyharju et al. 2001). 
 
In most tissues, type III collagen is co-expressed with type I collagen (Linsenmayer 1991). 
Changes in the distribution and increase in the production of collagens I and III occur in 
various diseases, like pulmonary fibrosis (Shahzeidi et al. 1993, Raghu et al. 1995). In the 
airways of OB patients, collagens I and III protein exists in subepithelial fibrotic lesions 
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(Yousem et al. 1992, Coers et al. 1999). In transbronchial biopsies, increased amounts of type 
III collagen deposition appear in clinically manifest OB (Zheng et al. 1999).  
 
4.5 Other pathways and molecules contributing to OB 
OB pathogenesis has been under active investigation, with several other pathways and 
molecular mechanisms found or suggested as taking part. These are presented in Table 5.  
 
5. Treatment options for OB  
As yet, for most OB patients, no therapeutic option is able to influence the progress of the 
disease. Although chronic rejection is strongly believed to be the main cause of OB, 
augmentation of immunosuppressive therapy rarely induces a longstanding positive effect 
(Boehler et al. 2003). Treatment results for OB in lung-transplant patients are still 
disappointing, and various strategies such as modification of the maintenance regimen 
(Knoop et al. 2004), addition of inhaled immunosuppressants (Iacono et al. 1996, De Soyza et 
al. 2001), total lymphoid irradiation (Diamond et al. 1998), photopheresis (O’Hagan et al. 
1999), allopurinol (Scott et al. 1992), methotrexate (Dusmet et al. 1996), and statins (Johnson 
et al. 2003), have undergone investigation.  
 
Use of newer immunosuppressive agents such as tacrolimus, MMF, sirolimus, and everolimus 
is increasing (Trulock et al. 2004). Tacrolimus and MMF have been effective in treatment of 
acute rejection, but their role in preventing OB long-term remains unclear (Treede et al. 
2001a-b, Bhorade et al. 2003, Knoop et al. 2004). In addition to their effect on lymphocyte 
proliferation, sirolimus and everolimus also show an antiproliferative impact on smooth 
muscle cells and on fibroblasts (Nair et al. 1997, Azzola et al. 2004).  Thus far, studies 
conducted on these agents in OB prevention have included only small numbers of patients, 
but the results have been promising (Cahill et al. 2003, Ussetti et al. 2003). However, despite 
the advances in immunosuppressive therapies, BOS/OB has a high incidence among lung 
transplant recipients, remaining, in the field of lung transplantation, the leading challenge. 
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NO=nitric oxide, iNOS=inducible nitric oxide synthase, ET-1=endothelin-1, FGF=fibroblast growth factor, IGF-
1= insulin-like growth factor, COX-2=cyclic oxygenase-2, MMP=matrix metalloproteinases, HO-1=heme 
oxygenase, ACE=angiotensin-converting enzyme 
Table 5. Pathways and molecules contributing to OB 
 
Molecule or agent Function Observations  
NO Mediator of immune 
defense, leucocyte 
adhesion, and 
vasorelaxation 
Decreased production in endothelium and in airway 
epithelium in OB patients (McDermott et al. 1997)  
 
Increased exhaled levels in lung transplant recipients with 
lymphocytic bronchiolitis and early OB (Fisher et al. 1998). 
 
Induction inhibits SMC proliferation and modulates immune 
responses in rat model of OB (Kallio et al. 1997). 
 
iNOS 
 
Synthesizer of  nitric 
oxide 
 
Strongly expressed in damaged airway epithelium and in 
inflammatory cells in OB patients (Mason et al. 1998). 
 
Up-regulation in fibroblasts and airway epithelium parallels 
onset and progression of fibrosis in rat and porcine models 
of OB (Romanska et al. 2000, Minamoto et al. 2002, 
Salminen et al. 2002). 
 
ET-1 
 
Vasoconstictor, growth 
factor for mesenchymal 
cells, inducer of adhesion 
molecule expression 
In human lungs upregulated with OB (Jeppsson et al. 1998), 
increased in rat model of OB (Aris et al. 2002), and blockade 
of ET receptors attenuates development of OB (Tikkanen et 
al. 2004). 
 
Upregulated in OB patients (Al-Dossari et al. 1995) and in 
rat model of OB (Aris et al. 2002). 
 
FGF 
 
 
IGF-1 
 
Mitogens and stimulators 
of fibroblasts 
 
 
Upregulated in BAL samples of BOS patients, and suggested 
as an early marker of OB (Charpin et al. 2000).  
COX-2 
 
 
Expression in acute and 
chronic inflammatory 
responses 
 
 
COX-2 induction parallels onset of inflammation and 
fibroproliferation in a porcine model of OB (Päiväniemi et 
al. 2004). 
 
MMP 
 
Key enzymes involved in 
extracellular matrix 
degradation and tissue 
remodeling 
 
Increase in sputum concentrations of MMP-9, and decrease 
in its tissue inhibitor-1 (TIMP-1) inversely correlates with 
airflow obstruction in lung transplant patients (Beeh et al. 
2001). 
 
MMP-2 and its activator membrane type 1 (MT1)-MMP 
localized in lymphocytes and in fibrotic areas in rodent 
model of OB (Inaki et al. 2004).   
 
MMP-2 and MMP-9 activity increases with concomitant 
rejection in porcine model of OB (Eerola et al. 2005) 
HO-1 
 
Cytoprotective protein, 
identified as a graft 
survival gene 
Increased in murine heterotopic airway rejection; deficiency 
accelerates development of OB lesions (Visner et al. 2003). 
 
ACE 
 
Increased in fibrotic 
disorders 
 
In rodent model of OB, presence of ACE in the 
fibroproliferative lesion demonstrated, and inhibition of 
ACE by captopril limits development of obliteration 
(Maclean et al. 2000). 
 
Phosphodiesterase-
4 
Mediator of inflammation 
 
Inhibition reduces macrophage infiltration and 
mesenchymal-cell proliferation in rat tracheal allografts 
(Roth-Eichhorn et al. 2001). 
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6. Experimental models of OB 
Clinical investigation of OB in human beings is restricted by the limited amount of biological 
material available from patients. To address this problem, several experimental animal models 
have been developed with either ortho- or heterotopic transplantation of lung, bronchial, or 
tracheal structures (Hertz et al. 1993, Al-Dossari et al. 1994, Huang et al. 1995, Ikonen et al. 
1998, Hausen et al. 1999). Orthotopic rat and porcine lung allografts exhibit changes similar 
to those in human OB (Al-Dossari et al. 1994, Ikonen et al. 1995, Hirt et al. 1999), but 
orthotopic transplantation techniques are very demanding and time-consuming, and 
development of OB lesions is slow and variable (Uyama et al. 1992, Al-Dossari et al. 1994, 
Ikonen et al. 1995). Heterotopic transplantation models are considered feasible and cost-
effective (Hele et al. 2001). In these models, the graft is usually implanted into the omentum 
or into subcutaneous pouches: one widely employed example is a model of heterotopic 
tracheal transplantation in rodents.  
 
The actual site of human OB is small bronchi and bronchioles, and in order to study smaller 
airways, porcine (Ikonen et al. 1998) and primate (Hausen et al. 1999) models have been 
developed for transplantation of bronchi and bronchioles. The porcine heterotopic bronchial 
transplantation model developed by our group exhibits histological changes similar to those of 
human OB following lung transplantation. Total epithelial destruction and permanent luminal 
obliteration occur rapidly in allografts without immunosuppression (Ikonen et al. 1998).  
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AIMS OF THE STUDY 
The focus of this study was to elucidate mechanisms in the development of post-transplant 
OB, employing a porcine heterotopic bronchial transplantation model. The specific aims of 
this study were to investigate in OB: 
 
• epithelial cell apoptosis (I) 
• the role of TNF-α (II) 
• the roles of PDGF, TGF-β, and CTGF (III) 
• the expression and distribution of collagens I and III (IV) 
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METHODS 
 
1. Porcine heterotopic bronchial transplantation model 
The animals were 48 non-related, random-bred domestic pigs weighing initially 20 kg. They 
received humane care in compliance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use 
of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health (NIH Publication No.86-23, revised 1985). The 
study protocol was accepted by the institutional committee for animal research and by the 
Uusimaa Provincial Administration, Finland. Special attention was given to anesthesia and 
pain relief during surgical procedures.  
 
1.1 Anesthesia 
Anesthesia was induced with intramuscular ketamine sulphate (10-15 mg/kg) (Pfizer, 
Brooklyn, NY, USA) azaperone (10-15 mg/kg) (Janssen Pharmaceutica, Beerse, Belgium), 
atropine sulphate (0.05 mg/kg) (Leiras, Turku, Finland), and intravenous sodium 
pentobarbital (6-12 mg/kg) (Orion, Turku, Finland). Intravenous diazepam (0.25 mg/kg) 
(Orion Pharma, Espoo, Finland) was given prior to intubation, and later, muscle relaxation 
was maintained with intravenous pancuronium bromide (2-4 mg) (Organon, Oss, Holland)   
(I, II, IV). In Study III, intravenous prophophol (1.5-2.5 mg/kg) (Abbott, Espoo, Finland) was 
used instead of pentobarbital and pancuronium bromide. During the surgical procedure the 
animals were ventilated with 40% oxygen and enflurane (Abbott). When the bronchial grafts 
were harvested, the pigs were anesthetized with 6 mg/kg ketamine sulphate and 6 mg/kg 
azaperone intramuscularly. At the end of follow-up, they were euthanized with a high 
intravenous dose of sodium pentobarbital.  
 
1.2 Surgery 
 
The surgical procedure consisted of left thoracotomy performed for removal of the caudal 
lobe (Figure 1A). Peripheral bronchial segments (1-2 cm in length and 1-2 mm in diameter) 
were dissected free of the surrounding lung parenchyma (Figure 1B). Bronchial implants were 
transplanted subcutaneously into the ventral side of each recipient (Figure 1C), each serving 
as both donor and recipient. Both autograft and allograft transplantations were performed. 
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Figure 1. Porcine heterotopic bronchial allograft model. 1A) Left caudal lung lobe. 1B) A bronchial segment 
prior to transplantation. 1C) Subcutaneous transplantation of bronchi. Each recipient received approximately 40   
implants. 
 
 
1.3 Post-operative medication 
Postoperative pain was controlled with diclophenic acid 37.5 mg (Novartis, Basel, 
Switzerland) intramuscularly, and keftriaxone 500 mg (Roche, Basel, Switzerland) was given 
for 3 days intramuscularly for infection control. For ulcer prophylaxis, perioperatively 
administered intravenous ranitidine 50 mg (Orion Pharma) was continued at a daily oral dose 
of 150 mg for 3 weeks. Oral kefalexin 500 mg (Orion) was given for 2 to 3 weeks. 
 
1.4 Graft harvesting 
Depending on the study protocol, the follow-up time ranged from 21 days to 3 months. On the 
pre-determined postoperative days, 1-3 bronchial segments were removed serially from each 
animal. Each harvested bronchial segment was cut into three portions. Portions for 
histological staining, immunohistochemistry of paraffin-sections, and for in situ hybridization 
were fixed in 10% normal buffered formalin solution. Portions for immunohistochemistry of 
frozen sections were embedded in Tissue-Tek™ and snap frozen in liquid nitrogen. Sample 
portions for determination of total collagen and for RNA isolation were also snap frozen. All 
frozen specimens were stored at -70°C. 
 
2. Study groups 
Study groups comprised control autografts and allografts, and allografts treated with various 
drug regimens. Each group comprised four animals. The following drugs were investigated 
either as a single treatment or in combinations to prevent OB (Table 6): 
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Cyclosporine A (CsA) (Novartis) was used in combination with Aza and MP or with 
everolimus and MP. The dose was 10 mg/kg/day orally and CsA administration began 3 days 
prior to the transplantation procedure. 
 
Everolimus (RAD, 40-O-(2-hydroxyethyl)-rapamycin) (Novartis) was used either with CsA 
and MP or as a single treatment at an oral dose of 1.5 mg/kg/day, started 3 days prior to 
transplantation. Dosage was based on a pharmacokinetic study (Maasilta et al. submitted). 
 
Methyl prednisolone (MP) (Pharmacia, New York, NY, USA) was given in combination with 
CsA and Aza or with CsA and everolimus at an oral dose of 20 mg daily. 
 
Azathioprine (Aza) (GlaxoSmithKline, Philadelphia, PA, USA) was given with Csa and MP 
at an oral dose of 2 mg/kg/day. 
 
Infliximab (Schering-Plough, Kenilworth, NJ, USA), a chimeric human/mouse anti-TNF-α 
monoclonal antibody was administered intravenously at a dose of 5 mg/kg. A single dose 
infusion was given preoperatively; 5 mg/kg was based on previous experiments in rats and 
pigs (Olmarker et al. 2001, Kulmatycki et al. 2001) and in human pharmacokinetics 
(Kavanaugh et al. 2000, Cornillie et al. 2001). 
 
Imatinib (Novartis), a tyrosine kinase inhibitor that targets PDGF receptors, c-kit, and V-abl 
was given as a daily oral dose of 10 mg/kg. The treatment was started 3 days prior to 
transplantation. The dose was based on clinical use (Druker et al. 2001) and on studies in 
rodent models (Savikko et al. 2003, Sihvola et al. 2003). 
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Table 6. Study groups 
Study Groups 
I 
Autografts 
Nontreated allografts  
CsA, Aza, MP - allografts 
CsA, everolimus, MP - allografts  (I, IV) 
Everolimus - allografts 
II 
Autografts 
Nontreated allografts 
Infliximab - allografts 
III 
Autografts 
Nontreated allografts 
Imatinib - allografts 
IV 
Autografts 
Nontreated allografts  
CsA, everolimus, MP - allografts (I, IV) 
 
 
 
3. Histologic analysis  
Formalin-fixed, paraffin-embedded samples were cut into 4-µm sections and hematoxylin-
eosin (H&E) stained. From each sample, 1 to 3 bronchi were analyzed. Histologic alterations 
(Table 7) were semiquantitatively graded on a scale from 0 to 3. Furthermore, in fibrotic 
areas, the relation between cellular and extracellular matrix components was scored as equal, 
<1, or >1. Percentages of normal epithelial cells, epithelial cells with metaplastic atypia 
(ciliated respiratory cells changing into squamous cells), and the pure basal cell layer of the 
remaining epithelium were also evaluated. In Study IV, luminal obliteration was evaluated by 
measurement of the area of the luminal plug and total luminal area with Olympus DP-Soft 
Version 3.1 software, and by calculating the relation between these areas.  
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 Table 7. Grading of histologic alterations 
Alterations  Scale used 
Epithelial destruction 
 
Bronchial wall (area from beneath the 
epithelium down to the cartilage) 
• inflammation, necrosis, fibrosis  
 
Cartilaginous  
• necrosis, proliferation  
 
Pericartilaginous (area surrounding the 
cartilaginous structures) 
• fibrosis, inflammation 
 
Total fibrosis (bronchial wall fibrosis 
and pericartilaginous fibrosis) 
0 = no alteration 
 
1 = mild alteration including a minor portion of the observed area 
 
2 = moderate, in which areas of pathologic alterations are equal to 
areas of normal tissue 
 
3 = severe alterations, in which pathologic changes are the 
predisposing component 
Luminal obliteration 
0 = no obliteration, (0-1 = incipient obliteration) 
1 = approximately one-third of the lumen occluded 
2 = two-thirds occluded 
3 = total occlusion 
4. Analysis of apoptotic cells 
The apoptotic index % (apoptotic cells/total number of cells) of the graft bronchial epithelium 
was evaluated preliminarily in H&E-stained sections based on apoptotic morphology. To 
further confirm the appearance of apoptotic cells in the epithelium of bronchial airways, we 
used in situ 3’-end labeling of apoptotic DNA (terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling, TUNEL) with the ApopTag Peroxidase Kit (Oncor, 
Gaithersburg, MD, USA). Sections 4 µm thick were cut from paraffin–embedded bronchial 
implants and placed on glass slides (SuperFrost® Plus, Menzel-gläser, Germany). These 
sections were dewaxed, rehydrated, and pretreated in 20 µg/ml proteinase K at room 
temperature (RT) for 15 min. Endogenous peroxidase activity was consumed by incubation in 
2% hydrogen peroxide in phosphate-buffered saline (PBS), pH 7.2, for 20 min. Terminal 
deoxynucleotidyl transferase (TdT) enzyme was used to catalyze the addition of digoxigenin-
labeled nucleotides to the 3’-OH ends of the fragmented DNA. After this, antidigoxigenin-
peroxidase solution was applied to the sections. Sections for which the TdT-enzyme was 
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omitted served as negative controls. A color reaction was developed with diaminobenzidine 
(DAB) and hydrogen peroxide. The sections were counterstained with methyl green. 
 
The counting of apoptotic cells in the epithelium was performed in 10 microscopic visual 
fields at x40 objective magnification. Only cells or cellular fragments with intense brown 
staining were considered positive. If several apoptotic bodies were visible in the same cluster, 
they were counted as one cell. Over 1% of apoptotic cells of the epithelium was considered  a 
high apoptotic index. 
 
5. Immunohistochemical analysis 
 
5.1 Frozen sections 
Sections 4 µm thick were cut and placed on glass slides, air-dried, fixed in acetone at -20°C 
for 20 min, and stored at -20°C until used. A three-layer indirect immunoperoxidase method 
was used with the following antibodies: mouse monoclonal antibodies against pig CD4+ and 
CD8+ cells (clones 74-12-4 and PT81B) (diluted at 5µg/ml and 1µg/ml) (VMRD Inc., 
Dullman, WA, USA), against human monocytes/macrophages, also reactive with porcine 
macrophages (clone MAC387) (5µg/ml) (Serotec, Oxford, UK), and against pig TNF-α 
(clone 9B4) (10µg/ml) (Endogen, Woburn, MA, USA). Before staining, the slides were re-
fixed in chloroform for 30 min at room temperature and then air-dried. The primary 
antibodies were diluted in 0.1% bovine serum albumin (BSA; Sigma, St. Louis, MO, USA) in 
TRIS-NaCl buffer (TBS), pH 7.4. The sections were first incubated with the primary 
antibody, (against CD4, CD8, and macrophages for 30 min, at RT, and against TNF-α for 18 
hours at +4°C), then with peroxidase-conjugated, rabbit anti-mouse Ig antibody (Dako A/S, 
Denmark) for 30 min at RT, and thereafter with a peroxidase-conjugated, goat anti-rabbit Ig 
antibody (Zymed, San Fransisco, CA, USA) for 30 min at RT. The secondary and tertiary 
antibodies were diluted in 50% normal pig serum in TBS. Between incubations, the slides 
were washed with TBS. The reaction was revealed by 3-amino-9-ethyl carbazole (AEC; 
Sigma) solution containing hydrogen peroxidase. Sections were counterstained with Mayer’s 
hemalun, and coverslips were aquamounted (Aquamount; Gurr, Poole, UK). Controls for 
TNF-α immunostaining were performed with mouse monoclonal IgG1 (X931, Dako) as a 
primary antibody. None of the controls showed positivity. 
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5.2 Paraffin-embedded samples 
Rabbit polyclonal antibodies against PDGF-A (sc-7958) (diluted at 4 µg/ml), PDGF-B (sc-
7878) (4 µg/ml), PDGFR-α (sc-338) (0.5 µg/ml), and PDGFR-β (sc-339) (0.67 µg/ml) (Santa 
Cruz Biotech. Inc, Santa Cruz, CA, USA), TGF-β1 (CPT001) (3.3 µg/ml) (Cell Sciences, Inc. 
Norwood, MA, USA), and CTGF (ab6992) (10 µg/ml) (Abcam, Cambridge, UK) served as 
primary antibodies in immunostaining with Vectastain Elite ABC Kit (Vector Laboratories 
Inc., Burlinghame, CA, USA). In the protocol, the samples were cut into 5-µm sections, and 
placed on glass slides. They were deparaffinized and hydrated through descending ethanol 
concentrations, and then pretreated in a microwave oven and incubated in 1.6% H202 in 
methanol to block endogenous peroxidase. After this, the sections were incubated in blocking 
(goat) serum for 30 min, followed by overnight incubation at +4ºC with the primary antibody. 
Subsequently, they were incubated with biotinylated goat anti-rabbit antibody at RT for 30 
min and finally with avidin/biotinylated enzyme complex for 30 min. All dilutions were made 
in Tris-buffered saline (TBS), pH 7.4, and between each step, the slides were rinsed in TBS. 
The reaction was revealed with AEC solution containing hydrogen peroxidase. The sections 
were counterstained with Mayer’s hemalun. For rabbit polyclonal antibodies, controls for 
immunostaining were performed with rabbit immunoglobulin fraction (X 0936, Dako) as a 
primary antibody. None of the controls showed positivity.  
 
5.3 Quantitation of immunohistochemistry 
The number of macrophages and cells positive for CD4, CD8, and TNF-α were counted 
separately in the epithelium, in the bronchial wall, and in the obliterative plug. Number of 
positive cells was counted in 10 randomly chosen microscopic fields in the epithelium and in 
five fields in the bronchial wall and obliterative plug. Number of TNF-α-positive epithelial 
cells and inflammatory cells among the epithelium were calculated separately. In addition, 
TNF-α-positive epithelial cells were divided according to weak or strong staining. The 
intensity of PDGF-A, PDGF-B, PDGFR-α, PDGFR-β, TGF-β1, and CTGF staining was 
scored from 0 to 3 as follows: 0=no visible staining, 1=cells with mild staining, 2=moderate 
intensity with multifocal staining, 3=intense diffuse staining. Staining intensity was scored 
separately for the epithelium and for fibroblasts, inflammatory and endothelial cells, and for 
the smooth muscle cell ring surrounding the bronchi. In each sample, 3 separate bronchi (if 
present) underwent analysis, the same bronchi being evaluated in histologic and 
immunohistochemical analyses. 
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6. Determination of total tissue collagen  
Total tissue samples were homogenized in distilled water and the hydroxyproline content 
determined from the homogenate. These homogenates were hydrolyzed in 6 N HCl for 3 
hours at 130°C, the HCl was evaporated, and the residue was dissolved in 20 mM HCl. The 
hydroxyproline was analyzed with high-pressure liquid chromatography (HPLC, Alliance 
System, Waters, MA, USA) and precolumn derivatization with 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate. The value obtained for hydroxyproline was then used to 
estimate the total collagen per mg of wet tissue, assuming that hydroxyproline comprises 
13.7% collagen by weight (Hamlin et al. 1971). 
 
7. Construction of cDNA clones for porcine proα1(I) collagen and proα1(III) collagen 
mRNAs 
 
Total RNA was extracted by an established method (Chomczynski et al. 1987) from 
experimental granulation tissue induced for 15 days by implantation of sterilized viscose 
cellulose sponges (5 x 5 x 10 mm, dry weight ~10mg, Cellomeda Oy, Turku, Finland) into 
subcutaneous pockets of recipient pigs. Random hexamers and oligo(dT) were used to prime 
reverse transcription of 1 µg of total RNA by Moloney Murine Leukemia Virus (M-MLV) 
reverse transcriptase under conditions suggested by the supplier (GIBCO BRL, Gaithersburg, 
MD, USA). Aliquots of cDNA were used for amplification by polymerase chain reaction 
(PCR) (AmpliTaq™, Perkin Elmer, Branchburg, NJ, USA) with oligonucleotide primers 
based on existing human, mouse, and rat sequences (Bernard et al. 1983, Genovese et al. 
1984, Ala-Kokko et al. 1989, Metsäranta et al. 1991, Glumoff et al. 1994) covering the 3’-
untranslated sequence of the mRNA. The reactions were cycled through denaturation at 94°C 
for 1 min, annealing at 50°C for 2 min, and extension at 72°C for 2 min. After 30 
amplification cycles, aliquots of the reactions were fractionated on 1.0 % agarose gels, and the 
specific fragments purified and cloned into the pGEM™-T Easy vector (Promega, Madison, 
WI, USA). Identification of the clones was performed by sequencing with the ABI Prism 377 
and dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster 
City, CA, USA). The sequences were deposited in the EMBL/GenBank database under 
accession numbers AJ289757 (pPCol1a1-1 for pig type I collagen mRNA) and AJ289758 
(pPCol3a1-1 for pig type III collagen mRNA). 
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8. Northern blotting 
Total RNA was extracted from the bronchial samples by the method of Chomczynski et al. 
(1987). Aliquots of total RNA (10 µg) were fractionated by electrophoresis on agarose gels 
and then transferred by blotting onto a nylon transfer membrane (MagnaGraph Nylon 
Transfer membrane; Micron Separations Inc., Westborough, MA, USA). cDNA clones 
specific for pig proα1(I)- and proα1(III) collagen mRNA served as hybridization probes, with 
clone pRGAPDH for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference 
probe. The clones were amplified by PCR and labeled with 32P-dCTP by random priming 
(High Prime DNA Labeling Kit, Boehringer Mannheim, Mannheim, Germany). After 
blotting, the membranes were UV-crosslinked and prehybridized. The hybridizations were 
performed at 42°C for 16 to 18 hours in hybridization solution (50% formamide, 1 M NaCl, 
1% sodium dodecyl sulfate (SDS), 5x Denhardt's solution, 10% dextran sulfate, and 100 
µg/ml herring sperm DNA). After hybridization, the filters were washed three times in 2x 
standard saline-citrate (SSC), (1x SSC is 0.15M NaCl and 0.015M sodium citrate), once in 
0.1% SDS at room temperature, and twice in 0.1x SSC and 0.1% SDS at 55°C. The bound 
probe was detected by autoradiography at -70°C with Kodak X-omat films. The relative 
intensity of the bands of pig proα1(I)- and proα1(III) collagen mRNAs were analyzed by 
scanning of exposed films by a densitometer (HP Scanjet IIc Scanner, Hewlett Packard Co., 
Edina, MN, USA), and the bands were quantified (Software, Bio Image, Ann Arbor, MI, 
USA). Results were corrected for minor variations in the amount of GAPDH mRNA in 
respective samples.  
 
9. In situ hybridization  
Vectors containing the cDNA inserts for pig proα1(I)- and proα1(III) collagen mRNA were 
linearized by appropriate restriction enzymes to synthesize antisense and sense probes with 
Sp6 and T7 RNA polymerases. Probes were labeled with digoxigenin-11-UTP with the DIG 
RNA labeling kit (Boehringer Mannheim). Concentrations of the transcripts were determined 
by serial dilution of the color reaction against known concentrations of labeled control RNA. 
Paraffin sections 4 µm thick were deparaffinized and hydrated through descending ethanol 
concentrations, and then pretreated in buffered proteinase K solution (10 µg/ml) at 37°C for 
30 min and fixed with 4% paraformaldehyde. For hybridization, the labeled complementary 
RNA (cRNA) probes were diluted in hybridization solution (20 mM Tris-HCl, pH 8.0, 5 mM 
EDTA, 0.3 M NaCl, 50% formamide, 10% dextran sulphate, 1x Denhardt's solution, 200 
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µg/ml sheared herring sperm DNA, yeast tRNA 200 µg/ml). Hybridization was performed in 
a humidified chamber at 50°C for 18 hours. After hybridization, the sections were 
sequentially washed in 5x SSC at 50°C for an hour, in 2x SSC/50% formamide at 65°C for 30 
min, and three times in NTE buffer (0.5 M NaCl, 10 mM Tris-HCl, 5 mM EDTA) at 37°C for 
10 min to reduce non-specific binding by the probe. For digestion of the unbound probe, the 
sections were treated with RNAase A (20 µg/ml in NTE buffer) at 37°C for 30 min, washed 
in NTE buffer at 37°C for 15 min, in 2x SSC/ 50% formamide at 65°C for 30 min, in 2x SSC 
at RT for 15 min, and finally in 0.1x SSC at RT for 15 min. Digoxigenin-labeled probes were 
detected following the methods of the DIG-detection Kit (Boehringer Mannheim) by use of 
antidigoxigenin antibody, and incubation at RT for 30 min. After digoxigenin detection, the 
sections were incubated for 16 hours in color substrate. The sections were then counterstained 
with Mayer's hemalum and cover-slipped with aqueous-based mounting medium.  
 
9.1 Quantitation of in situ hybridization 
Of each tissue section hybridized with the antisense probe, a control was hybridized with the 
sense probe. A cell was defined as positive when cytoplasmic red-brown staining against the 
pale staining background was visible with the antisense but not with the sense probe. 
Distribution and number of cells positive for proα1(I)- and proα1(III)collagen mRNA were 
analyzed separately in the obliterative plug, in the bronchial wall, and in the pericartilaginous 
area. Positive cells were counted in five randomly chosen microscopic fields from each area. 
 
10. Statistical analysis 
 All data are expressed as mean + SEM. Variations between any two groups were analyzed 
with the Mann-Whitney U-test, and variations between multiple groups were calculated by 
the nonparametric Kruskal-Wallis one-way analysis by ranks. The rank sums were then used 
for Dunn's test at a significance level of 5% (Medstat, Astra Group A/S, Copenhagen, 
Denmark). Values of p<0.05 were considered significant. For correlation analysis, 
Spearman’s rank correlation (Statistica v. 5, StatSoft Inc., Tulsa, OK, USA) was used. 
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RESULTS  
 
1. Porcine heterotopic bronchial transplantation model (I-IV)  
Subcutaneously transplanted bronchial segments, 1 to 2 cm in length and 1 to 2 mm in 
diameter were serially removed in the porcine heterotopic bronchial transplantation model, for 
study of autografts and allografts either nontreated or treated with various drug regimens. No 
serious adverse effects occurred during the drug treatments.  
 
1.1 Autografts 
Normal ciliated bronchial epithelium was maintained through the study periods with no 
luminal obliteration in autograft bronchial transplants after post-ischemic injury on day 3 
(Figure 2). Bronchial wall inflammation and fibrosis as well as pericartilaginous inflammation 
were mild. Bronchial cartilage remained viable, and formation of new cartilage was apparent. 
In the bronchial wall, CD4+ and CD8+ lymphocytes as well as macrophages appeared in only 
small amounts.  
 
1.2 Nontreated allografts 
Nontreated allografts lost their epithelial covering almost completely within one week. 
Concomitantly, inflammatory cell infiltrates consisting mainly of lymphocytes and 
macrophages in the bronchial wall increased. Fibroproliferative tissue protruding into the 
bronchial lumen was first seen on day 7, and luminal obliteration was complete within 3 
weeks (Figure 2). In nontreated allografts, bronchial wall fibrosis consisted of fibroblasts and 
extracellular matrix components in equal proportions. It increased from mild to moderate by 
day 10, persisting thereafter. Pericartilaginous inflammation and cartilaginous necrosis 
proceeded gradually to severe within one month. These histological changes differed 
significantly (p<0.05) from those of autografts. In correlation analyses, degree of epithelial 
destruction from day 4 onwards correlated with that same day’s obliteration (r=0.42-0.99, 
p<0.001) and future obliteration (r=0.67-0.96, p<0.001). Numbers of CD4+, CD8+ 
lymphocytes, and macrophages were elevated in comparison to the numbers of these cells in 
autografts (p<0.05). CD8+ lymphocytes were predominant throughout follow-up.  
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 (p<0.05 in comparison to 
nontreated allografts). In these grafts, mild to moderate bronchial wall inflammation was 
encountered, but mural fibrosis remained mild, consisting mainly of cellular components. 
Similarly to autografts, bronchial cartilage remained viable, and cartilagineous proliferation 
occurred.  
 
2. Epithelial apoptosis in a porcine bronchial model of OB (I) 
Only on day 3, in autografts and in the allografts on triple therapy of CsA, everolimus, and 
MP, were metaplastic epithelial atypia and pure basal cell layers, and moderate epithelial 
destruction observable, and the apoptotic index was at its highest (1.0+0.5). From day 7 
onwards, normal ciliated epithelial coverage prevailed through the 3-month follow-up, and 
the apoptotic indexes remained low (<1%).  
 
In nontreated allografts, the epithelium underwent total destruction within 7 days, and the 
apoptotic index analyzed only on day 3 was slightly higher than in autografts. In the group 
receiving the triple therapy of CsA, Aza, and MP, mainly atypic epithelial cells or pure basal 
cell layers were present on day 3, after which the remaining epithelium recovered slightly. In 
some grafts even normal epithelial cells were detected up to day 14. Apoptotic indexes were 
elevated at all observation points, being highest on days 7 (2.8+0.9, p<0.05 in comparison to 
autografts) and 14 (3.4+2.6). In most allografts treated solely with everolimus, normal 
epithelial coverage prevailed at most observation points, but on day 3 and at late time-points, 
a more atypical type epithelium or the pure basal cell layer was encountered. The proportion 
of apoptotic cells in the epithelium on day 3 (1.4+0.6) was similar to that of other groups. 
Apoptosis of epithelial cells began to increase significantly on day 21 (2.7+1.1, p<0.05 
compared with autografts) together with progressive epithelial destruction. The apoptotic 
index remained high in the samples with assessable epithelium on days 28 (1.9+.4) and 45 
(2.2+0.1, p<0.05 compared with autografts). 
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Figure 3. Effect of immunosuppression in bronchial allografts. Histological changes are graded on a    
semiquantitative scale of 0 to 3. Data shown until total obliteration or until 3 months. All data expressed as 
mean+SEM. 
 
3. TNF-α in a porcine bronchial model of OB (II) 
Epithelial cells and inflammatory cells among the epithelium showed positivity for TNF-α. In 
the bronchial wall, macrophages, lymphocytes, occasional endothelial cells, smooth muscle 
cells, and fibroblasts expressed TNF-α. TNF-α expression was up-regulated in the allografts 
in comparison to autografts (p<0.05 from day 7 onwards). Infliximab treatment led to slowed 
epithelial loss and luminal obliteration early in the disease process (p<0.05), and the normal 
epithelium prevailed longer in the treated allografts. Treated allografts showed milder 
bronchial-wall (p<0.01 on days 4, 7, and 21) and pericartilaginous inflammation (p<0.05 on 
days 4, 7, and 11) and milder fibrosis (p<0.05 on days 11 and 14) than in nontreated 
allografts. 
 
The number of TNF-α-positive epithelial cells and inflammatory cells among the epithelial 
cells was lower in treated than in nontreated allografts (p<0.05 on day 4). Recruitment of 
CD8+ lymphocytes in the epithelium was diminished during the first week (p<0.05), and 
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numbers of macrophages were lower on day 4 (p<0.05). In the bronchial wall, the number of 
CD8+ lymphocytes was similarly reduced on days 2, 4, and 7 (p<0.05), and numbers of 
macrophages were significantly lower on day 7.  
 
The number of TNF-α-positive epithelial cells on days 4, 7, and 11 correlated with the 
epithelial damage (r=0.62, p<0.001) and obliteration (r=0.67, p<0.001) on the same day or at 
future time points (r=0.39-0.74, p<0.05) (r=0.33-0.86, p<0.001). In the bronchial wall, the 
number of TNF-α-positive cells on days 7, 11, 14, and 21 correlated with obliteration on the 
same day or at future time points (r=0.43-0.62, p<0.05) (r=0.49-0.82, p<0.01).  
 
4. PDGF, TGF-β, and CTGF in a porcine bronchial model of OB (III) 
In autografts retaining normal bronchial histology, epithelial expression of PDGF-A and of 
PDGF receptors was mainly mild, whereas PDGF-B and TGF-β expression was moderate. In 
the bronchial wall, the expression of growth factors was generally mild, except that of CTGF, 
which ranged from moderate to intense.  
 
In nontreated allografts, epithelial destruction was almost complete by day 7, being slightly 
less extensive in the treated allografts. Obliteration of the bronchial lumens was slower in the 
treated group than in the nontreated one (p<0.05 on day 11). Bronchial wall fibrosis increased 
gradually in both allograft groups from mild to moderate. Imatinib treatment reduced 
inflammatory cell infiltrates in the bronchial wall and in the pericartilaginous area (p<0.01 on 
day 11 in comparison to nontreated allografts). Furthermore, it reduced recruitment of CD4+ 
lymphocytes (p<0.001 on days 11 and 14), of CD8+ lymphocytes (p<0.001 on days 7 and 14), 
and of macrophages (p<0.05 on days 4, 7 and 14).  
 
In allograft epithelium on day 4, expression of growth factors was moderate, except that 
treated grafts showed mild expression of PDGF-A (p<0.01 in comparison to nontreated 
allografts), and of TGF-β. Expression of PDGF-A, PDGF receptors, and of TGF-β was 
elevated (p<0.05) in the nontreated allografts when compared to autografts in most cell types 
at all time points. In the bronchial wall of all allografts, fibroblasts and smooth muscle cell 
rings showed moderate positivity for PDGF-A. In endothelial cells it was mild. In 
inflammatory cells of nontreated allografts, moderate positivity for PDGF-A appeared, 
whereas in treated allografts it was mild (p<0.05 on days 4, 7, 11). PDGF-B expression was 
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similar in all groups, being mainly mild. Fibroblasts and inflammatory cells showed milder 
positivity for the PDGF receptors in the treated than in the nontreated allografts (for fibroblast 
p<0.05 through the follow-up for PDGFR-α, and for PDGFR-β on days 7 and 11, and for 
inflammatory cells p<0.05 on days 4 and 14 for PDGFR-α, and on day 7 for PDGFR-β).  
 
In the endothelium, receptor expression was mild in both groups, except on day 7, when it 
was moderate in nontreated allografts (p<0.05 for PDGFR-α, p<0.001 for PDGFR-β). In 
smooth muscle cell rings, mild to moderate PDGF receptor expression existed in both groups. 
On day 7, PDGFR-β expression was more intense in nontreated allografts (p<0.05). In both 
groups, TGF-β positivity in fibroblasts was moderate and in inflammatory cells moderate to 
intense. In smooth muscle cells it peaked by day 11, decreasing thereafter. In the endothelium, 
TGF-β expression was mild, except on day 7, when it peaked at moderate in nontreated 
allografts. CTGF expression in both groups ranged from moderate to intense. 
 
5. Collagens I and III in a porcine bronchial model of OB (IV) 
In situ hybridization revealed type I and III collagen mRNA nearly exclusively in fibroblasts 
and in occasional smooth muscle cells. In autografts, the number of cells expressing type I 
and III collagen transcripts decreased by day 14 and remained low thereafter. In early 
obliterative lesions of nontreated allografts, cells positive for collagen I and III mRNA existed 
in equal numbers. From day 14 onwards, the majority of the positive cells were expressing 
type III collagen mRNA. In the bronchial wall, fibroblasts expressing collagen III mRNA 
started to increase on day 14 and were significantly (p<0.05) augmented on days 21 and 30 
compared to numbers of autografts. The dominance of fibroblasts showing a positive signal 
for type III collagen mRNA was evident at all assessment points. In immunosuppressed 
allografts, the pattern of fibroblast numbers expressing type I and III collagen mRNAs 
resembled that of autografts. No similar increase appeared in number of collagen III mRNA-
positive cells compared to collagen I mRNA-positive cells as it did in nontreated allografts. In 
immunosuppressed allografts, at some assessment points cells positive for collagen I and III 
mRNA were abundant in the pericartilaginous area, even in the total absence of positivity in 
the bronchial wall. 
 
Quantification of collagen I and III mRNA of the grafts showed no significant differences 
between the collagen types between groups. In all groups, however, in situ hybridization 
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detected the majority of positive cells in the pericartilaginous area. Comparison of absolute 
cell numbers in this area in autografts and in immunosuppressed allografts revealed a 
preponderance of collagen I mRNA to type III mRNA expression in fibroblast-like cells, 
whereas nontreated allografts showed the opposite. Total collagen in nontreated allografts 
decreased during follow-up to below the level of total collagen in native bronchial tissue. An 
increased total collagen content was evident in autografts and in immunosuppressed allografts 
at all assessment points, with p<0.05 on days 7, 21, and 60 between nontreated allografts and 
autografts.  
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Summary of the results presented in the thesis. 
 Main findings 
Epithelial apoptosis (I) 
 
In nontreated and in inadequately immunosuppressed allografts, apoptotic 
indexes of the epithelium increased with concomitant epithelial destruction. 
In allografts with immunosuppression adequate to prevent epithelial 
destruction, and in autografts, well-preserved epithelium was maintained 
with low apoptotic indexes. 
 
TNF-α (II) 
 
In the epithelium, numbers of TNF-α-positive epithelial and inflammatory 
cells and of macrophages were significantly lower in infliximab-treated than 
in nontreated allografts on day 4. In the epithelium and bronchial wall, 
invasion of CD8+ lymphocytes significantly decreased during the first week. 
TNF-α inhibition reduced inflammation, rate of epithelial loss, fibrosis, and 
obliteration early in OB development. 
 
PDGF, TGF-β, CTGF (III) 
 
Up-regulation of PDGF-A, PDGF receptor α and β, and TGF-β expression 
occurred in allografts, whereas PDGF-B and CTGF expression was similar 
between auto- and allografts. Imatinib, an agent targeting PDGF receptors, 
modified the inflammatory responses and also expression patterns of PDGF-
A and PDGF receptors in allografts. 
 
Collagens I and III (IV) 
 
Few fibroblasts expressed type I and III collagen mRNA in autografts and in 
allografts with CsA, everolimus, and MP therapy. In nontreated allografts, 
number of cells expressing collagen III mRNA increased parallel to the 
developing obliteration and fibrosis. 
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DISCUSSION 
 
Obliterative bronchiolitis in lung transplants is considered primarily to be the manifestation of 
chronic rejection. It remains the major barrier to long-term success after lung transplantation. 
Although clinical and experimental studies have provided substantial knowledge of the 
pathophysiology of OB, options for its prevention are still limited. Better understanding of the 
development of OB will lead to insights for future therapeutic interventions and preventive 
measures. To address this, the study focused on the mechanisms of OB in a porcine 
heterotopic bronchial transplantation model.   
 
1. Porcine heterotopic bronchial transplantation as a model of OB  
Because OB lesions in man take months to years to develop (Boehler et al. 2003), detailed 
studies of the pathophysiological mechanisms of OB are difficult to carry out. Our group has 
developed a heterotopic porcine bronchial transplantation model in which changes similar to 
human OB occur (Ikonen et al. 1998, Uusitalo et al. 1999). In subcutaneously implanted 
bronchial allografts, total obliteration develops within 3 weeks, but with immunosuppressive 
regimens this process is delayed or prevented. Neovascularization of the transplanted bronchi 
is observable within a few days (Salminen et al. 2000). Despite an initial anoxic period, 
autografts show normal bronchial structures, indicating that the obliterative changes in 
allografts are not due to ischemic injury. In nontreated allografts, the epithelium sloughs off 
within a week with a simultaneous influx of inflammatory cells. Before total epithelial loss, 
the epithelial cell type changes from cuboidal to squamous. This is followed by development 
of human OB-like fibrotic lesions (Tazelaar et al. 1994, Wallace et al. 2003); fibrous tissue 
plugs protrude into the bronchial lumen and gradually fill it, forming a dense scar. Similar to 
this, airway inflammation and epithelial injury are suggested to initiate the development of 
OB in human lung allografts (Hruban et al. 1988, Paradis et al. 1993, Reichenspurner et al. 
1995). In bronchial grafts, the inflammatory cell infiltrates consisted of CD4+, CD8+ 
lymphocytes and macrophages. CD8+ cells predominated, a feature characterized also in 
porcine orthotopic lung transplantation models (Al-Dossari et al. 1994, Allan et al. 2002) and 
in OB patients (Holland et al. 1990, Milne et al. 1994, Whitehead et al. 1995).  
 
In bronchial allografts, prevention of the obliterative process was achieved with the 
combination therapy of CsA, MP, and everolimus. Conventional triple therapy of CsA, Aza, 
and MP failed, however, to prevent OB in our model, despite the relatively high whole-blood 
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levels of CsA (583±225 ng/ml) (Salminen et al. 2000). The everolimus dose of 1.5 mg/kg was 
high in comparison to dosage in clinical transplantation, but this dose or even higher has been 
used in several experimental lung transplantation models (Serkova et al. 2000, Hausen et al. 
2000a-b), and we chose it based on our pharmacokinetic and safety study in pigs (Maasilta et 
al. submitted).   
 
Models of heterotopic lung transplantation are technically less demanding and less time- 
consuming than are models of orthotopic whole lung transplantation. In contrast to the widely 
used rat or mouse tracheal heterotopic transplantation models (Hertz et al. 1993, Huang et al. 
1995, Koskinen et al. 1997), we transplanted small bronchi close to the bronchioles, the actual 
site of OB. The main difference between bronchi and bronchioles is the presence of 
cartilaginous structures and submucosal glands in bronchi. As an advantage over rodent 
models, this experimental set-up provided the opportunity to investigate the development of 
OB in serial samples from the same animal. In the porcine model, we have also explored 
bronchi of larger diameter (Maasilta et al. 2000), terminal bronchioles without cartilage 
(Salminen et al. 2002), and lung tissue implants (Ikonen et al. 1998, Salminen et al. 2000). 
However, evaluation of small bronchi has proven the simplest and most reliable method to 
assess the developing histopathologic changes in our model.  
 
All experimental models have limitations when compared to clinical lung transplantation. In 
our model, disruption of bronchial vasculature occurs until neovascularization takes place, 
and this contributes to the early changes observed in all grafts. Due to this initial graft 
avascularity, the administration of immunosuppressive drugs should begin a few days prior to 
transplantation. Furthermore, bronchial grafts lack an air-epithelial surface, constant airflow, 
and clearance of secreted mucus. The pace of OB is accelerated in comparison to the slow 
disease progression in actual lung transplant patients. On the other hand, this feature is 
beneficial to orthotopic lung transplantation models, in which OB changes take months to 
develop (Al-Dossari et al. 1994, Ikonen et al 1995). Thus, with its characteristics of invariable 
and rapid airway obliteration and histopathologic changes similar to those in human OB, our 
large-animal model provides a useful tool for exploration of the pathogenesis of OB. 
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2. Apoptotic death contributes to epithelial cell loss in OB 
In OB pathogenesis, epithelial loss is considered a prerequisite for luminal obliteration 
(Mauck et al. 1996, Ikonen et al. 2000, Adams et al. 2000). We found a high proportion of 
apoptotic epithelial cells prior to total epithelial destruction in bronchial allografts with 
inadequate immunosuppression. In contrast, similar to control autografts, allografts with 
adequate immunosuppression showed only a few apoptotic epithelial cells.  
 
Activated recipient T cells infiltrating the graft are the primary initiators of the apoptotic 
cascade in donor endothelial, epithelial, and parenchymal cells (Zavazava et al. 2000). In our 
study, nontreated allografts exhibited an influx of CD4+ and CD8+ lymphocytes, and of 
macrophages, with a predominance of CD8+ cells (II, III). In allografts developing bronchial 
obliteration, inflammatory cell infiltrates were present in abundance in the bronchial wall and 
also to some extent among the epithelial cells.  
 
One possible mechanism of T cell-induced apoptosis in OB might be a Fas/FasL interaction 
and the perforin/granzyme-mediated pathway. Increased expression of Fas on bronchial 
epithelial cells, together with up-regulated FasL on infiltrating mononuclear cells, appears in a 
rat model of OB (Yagyu et al. 1997). These findings are supported by biopsy specimens of 
acute lung rejection that show a similar increase in Fas/FasL expression (Bittmann et al. 
2004). Granzyme B and perforin expression is associated with acute lung rejection (Clement 
et al. 1994, Bittmann et al. 2004), and in experimental OB, allografts produce more granzyme 
B than do isografts (Neuringer et al. 2000). Furthermore, T cells produce IL-2, which in turn 
induces the release of proapoptotic cytokines like TNF-α (Squier et al. 1995, Ross et al. 
1999). We found that the inflammatory cells in bronchial allografts undergoing rejection 
showed high levels of TNF-α expression (II), suggesting that epithelial cell apoptosis in these 
grafts were at least partly mediated via TNF-α signaling. 
 
In adequately immunosuppressed allografts, the bronchial epithelium remained intact, and 
apoptotic indexes resembled those of autografts, although degree of inflammation was 
histologically similar to that of other allograft groups. CsA and everolimus both inhibit IL-2- 
driven T cell stimulation and have a synergic effect (Schuler et al. 1997, Schuurman et al. 
1997). Even though T cells were present in CsA- and everolimus-treated grafts, it is likely 
that their activity was sufficiently reduced to prevent initiation of epithelial apoptosis and 
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destruction. This observation would point to the central role of epithelium-preserving 
therapies in prevention of OB.  
 
Graft reperfusion after lung transplantation is considered a strong inducer of epithelial and 
pneumocytic apoptosis (Fischer et al. 2000a-b, Stammberger et al. 2000, Shaw et al. 2001, 
Rivo et al. 2004, Yamashita 2004). On day 3, degrees of epithelial destruction and extent of 
epithelial cell apoptosis in allografts and in autografts were relatively similar. Because 
neovascularization also occurs by day 3 (Salminen et al. 2000), we speculate that graft 
reperfusion may have an impact on the high initial apoptotic indexes. High early apoptotic 
rate may also reflect initial injury caused by the transplantation procedure. In allografts 
regaining epithelial integrity, the apoptotic activity was low thereafter, whereas in nontreated 
allografts epithelial loss proceeded rapidly after initial injury. Inadequately 
immunosuppressed allografts underwent more slowly progressing epithelial destruction, and 
in these allografts, apoptotic activity of the epithelium remained elevated, implying epithelial 
damage and development of OB.  
 
Lung transplant patients with OB have been reported to have more apoptotic epithelial cells in 
transbronchial biopsy specimens than do those without OB (Hansen et al. 2000). In a rodent 
tracheal model, the number of apoptotic epithelial cells in rejected allografts was elevated. 
This portion was under 5% of the total epithelial cell number (Neuringer et al. 2002). We 
observed similar phenomena in our bronchial transplants. Because phagocytes rapidly clear 
the apoptotic bodies, the number of apoptotic cells at a certain observation point may lead to 
underestimation of the actual apoptotic rate. It is thus likely that even minor increases in the 
apoptotic rate contribute significantly to graft loss.  
 
In experimental models, epithelial cell necrosis occurs after lung transplantation (Fischer et al. 
2000b, Neuringer et al. 2002). It is inevitable that necrotic cell death also contributed to loss 
of epithelium in the bronchial grafts. However, we demonstrated that high apoptotic activity 
in conjunction with the changes in epithelial morphology and destruction signaled OB 
development. Immunosuppression that was effective in preventing alloimmune activation also 
led to a reduced rate of epithelial apoptosis, indicating that in our model increased apoptotic 
activity is primarily a result of alloimmune injury. This is further evidence that in OB, 
apoptotic death of epithelial cells is an important mechanism in the events leading to graft 
deterioration.  
 53
3.   TNF-α mediates epithelial injury and inflammatory and fibroproliferative changes   
in  OB  
 
A correlation appeared between expression of TNF-α and epithelial injury and obliteration. 
Inhibition of TNF-α delayed onset of OB by reducing inflammation, especially the CD8+ 
lymphocytes, and delayed the process of epithelial destruction and luminal occlusion.  
 
The multiple functions of TNF-α are considered crucial in the initiation and maintenance of 
the inflammatory cascades (Kollias et al. 1999). By binding TNF-α, infliximab reduces 
leukocyte trafficking and diminishes expression of adhesion molecules and chemokines 
(Taylor et al. 2000, Smeets et al. 2003), and also inhibits angiogenesis (Maini et al. 1999). 
Furthermore, by binding membrane-bound TNF-α, infliximab is capable of inducing 
apoptosis in T lymphocytes (Van den Brande et al. 2003, Di Sabatino et al. 2004). On the 
other hand, in patients with Crohn’s disease, infliximab reduces intestinal epithelial cell 
apoptosis (Zeissig et al. 2004). In OB, inflammatory cell invasion is one of the key events 
(Reinsmoen et al. 1993, Neuringer et al. 1998, Boehler et al. 1999, Neuringer et al. 2000, 
Maasilta et al. 2001); in our model, this was attenuated in infliximab-treated bronchial 
allografts, and better graft preservation was evident. Likely explanations for the lower grade 
of rejection were the ability of infliximab to down-regulate chemokines and adhesion 
molecules as well as directly to inhibit the lymphoproliferative and cytotoxic actions of TNF-
α. Induction of T cells and inhibition of epithelial cell apoptosis may also have occurred.  
 
Inhibition of TNF-α had the greatest influence on the number of CD8+ lymphocytes and to 
some extent on macrophages. This may have occurred because the rapid influx of 
inflammatory cells was largely due to CD8+ lymphocytes. In addition to the decreased 
inflammation, reduced bronchial wall fibrosis was evident in anti-TNF-α antibody-treated 
allografts. TNF-α is involved in the development of lung fibrosis (Zhang et al. 1997, Brass et 
al. 1999), and in OB, TNF-α has been suggested to up-regulate the expression of profibrotic 
growth factors (Aris et al. 2002). Our findings support the profibrotic role of TNF-α in OB 
development.  
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The potential of TNF-α inhibition in acute and chronic lung rejection has previously been 
explored in rodent models. In studies of acute rejection, either polyclonal anti-TNF-α 
antibodies (Saito et al. 1993) or neutralizing TNF-α antisera (DeMeester et al. 1993) have 
been administered. The results were contradictory, with the former study showing no benefit 
from TNF-α inhibition, while the latter showed significant attenuation of acute rejection in 
the treatment group. In chronic rejection studies, treatment with serial doses of antibodies 
against TNF-α (Smith et al. 2001) or with TNF-α-soluble receptor (Aris et al. 2002) prevents 
or delays OB development. Recently, reduction in OB was linked to diminished intragraft 
TNF-α mRNA and protein expression after treatment with inhibitors of p38 kinase or poly 
(ADP)-ribose synthetase (Farivar et al. 2004a-b).  
 
Considering the initial avascularity of our bronchial grafts, we administered the drug infusion 
prior to the removal of the left lung lobe.  Thus, infliximab was already present in the tissue at 
the time of subcutaneous implantation. After infliximab treatment, we observed a significant 
delay, but as expected, no prevention of OB. Repeated drug administration may have resulted 
in extended survival, although in humans, at a 5-mg/kg dose, infliximab is detected in the 
serum up to 8 to 12 weeks (Kavanaugh et al. 2000, Cornillie et al. 2001). The dosing interval 
is between 6 and 12 weeks for disease-suppressing activity in chronic inflammatory diseases 
(Braun et al. 2003). 
 
Because various cytokines participate in the rejection process (Boehler et al. 1999, Neuringer 
et al. 2000), inhibition of a single cytokine is ineffective in preventing the progression of the 
obliterative process. Our results demonstrated, however, that inhibition of TNF-α with 
infliximab, an anti-TNF-α antibody widely used in clinical practice, ameliorated the 
development of OB in transplanted small airways. This study further confirms that TNF-α 
may play a role in OB development by promoting inflammation and epithelial injury, and 
suggests that in lung transplant recipients, inhibition of TNF-α may prove beneficial. 
 
4. PDGF and TGF-β play a role in OB pathogenesis  
Our study demonstrated up-regulated expression of PDGF-A, of PDGF receptors, and of 
TGF-β in rejection of bronchial allografts. Imatinib treatment reduced the extent of 
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inflammatory changes and the rate of the obliterative process, and it modified the expression 
patterns of PDGF-A and PDGF receptors. 
 
In rodent tracheal allografts, the expression of PDGF-A, of PDGFR-α, and of PDGFR-β is to 
some extent upregulated, whereas PDGF-B positivity is more prominent in syngeneic grafts 
(Kallio et al. 1999). In some experimental and clinical studies, however, PDGF-B expression 
in OB increases (Hertz et al. 1992, Bergmann et al. 1998, Aris et al. 2002). Induction of 
PDGFR-β synthesis is considered crucial to chronic vascular rejection (Rubin et al. 1988, 
Savikko et al. 2003). Our finding that, despite the mild expression of PDGF-B, PDGFR-β was 
markedly upregulated in allografts supports previous observations (Savikko et al. 2001). An 
explanation for this phenomenon may be the low levels of PDGF-B, which in turn activate 
PDGFR-β synthesis.  
 
TGF-β has been detected in OB at sites of inflammation and fibrosis (El-Gamel et al. 1999) 
and is suggested to serve as an OB marker (Charpin et al. 1998, El-Gamel et al. 1999). In 
rodent tracheas, blocking of TGF-β binding to its receptor type III or blocking TGF-β 
downstream signaling through Smad3 reduces intraluminal fibrosis (Liu et al. 2002, Ramirez 
et al. 2004). In our porcine bronchial allografts, that high levels of TGF-β expression were 
encountered supports the role of TGF-β as an important mediator in OB. TGF-β is thought to 
function as the main up-regulator of CTGF and can induce a prolonged CTGF response (Xie 
et al. 2005). Despite the mild staining of TGF-β in autografts, CTGF expression between 
autografts and allografts was uniform. High CTGF expression associates with various fibrotic 
disorders, but in contrast, normal tissue expression of CTGF can also be very prominent 
(Moussad et al. 2000). In our model, the short avascular period may have up-regulated many 
mediators. The expression of CTGF may be up-regulated also by other growth factors, 
autoinduction, and physiological factors (Igarashi et al. 1993, Oemar et al. 1997, Riser et al. 
2000). It is probable that TGF-β-independent regulation of CTGF occurred in bronchial 
grafts.  
 
Imatinib had a strong influence on the number of CD4+ and CD8+ lymphocytes and on 
macrophages, suggesting its having immunosuppressive properties. In vitro studies have also 
shown that imatinib inhibits activation and proliferation of CD4+ and CD8+ T cells in 
addition to dendritic cells (Appel et al. 2004, Cwynarski et al. 2004, Dietz et al. 2004, 
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Seggewiss et al. 2005). In mice, it inhibits the delayed-type hypersensitivity reaction (Dietz et 
al. 2004). The effect of imatinib on T-cell function is independent of v-Abl, c-Kit, and PDGF 
receptors (Dietz et al. 2004), and recently it was suggested to occur via inhibition of tyrosine 
kinase LCK in the TCR signaling cascade (Seggewiss et al. 2005). In addition, imatinib 
reduced IL-2 production (Seggewiss et al. 2005).  
 
Those findings on imatinib’s effect on T cell signaling in vitro may apply to our work as well. 
However, PDGF plays a crucial role in inflammatory responses by acting as a significant 
mediator between macrophages and T cells, and by up-regulating and amplifying 
inflammatory reactions (Daynes et al. 1991, Brody et al. 1992, Morisaki et al.1994, Krettek et 
al. 2001). Furthermore, in experimental OB, depletion of recipient macrophages leads to a 
significant decrease in graft PDGF mRNA expression and in rate of obliteration (Oyaizu et al. 
2003). In our model, in rejected bronchial allografts, inflammatory cells strongly expressed 
PDGF-A and PDGF receptors, and imatinib significantly reduced this. These findings suggest 
that attenuation of T cell responses may have occurred through interruption of PDGF 
signaling between macrophages and T cells and inhibition of PDGF receptor function on T 
cells. In our imatinib-treated grafts, decreased endothelial expression of PDGF receptors 
probably diminished the extent of cellular infiltration into the grafts, although inhibition of 
other T cell signaling mechanisms may also have been involved. 
 
In rat studies, intraperitoneally administered CGP 53716, a precursor molecule of imatinib, 
with or without CsA, prevents or delays development of OB (Kallio et al. 1999, Tikkanen et 
al. 2003). CGP 53716 affects solely fibroblasts and smooth muscle cells, and thus the authors 
suggest that its effect is mediated via PDGF receptor inhibition. In experimental aorta and 
heart transplantation, imatinib in combination with CsA does not affect the staining intensity 
of PDGF-A, nor the numbers of macrophages (Sihvola et al. 2003). However, in rodent 
kidney transplantation, this combination reduces the number of graft-infiltrating CD4+ cells 
and macrophages and reduces PDGF ligand and receptor expression and chronic rejection 
(Savikko et al. 2003); the authors detected no staining of c-kit or v-Abl, suggesting that 
imatinib functions via PDGF receptor signaling. Intraperitoneally injected imatinib reduces 
pulmonary fibrosis in mice (Daniels et al. 2004). These authors suggest that imatinib also 
inhibits TGF-β signaling in fibroblast cultures through c-abl, a member of the Abl family of 
kinases. In our study, the effect of imatinib on fibroblasts was evident as reduced expression 
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of PDGF receptors and delayed obliteration. Because imatinib did not affect TGF-β levels, we 
speculate that in bronchial allografts imatinib interferes with PDGF signaling pathways. 
 
This study confirms that in OB, PDGF and TGF-β function as mediators. An agent inhibiting 
PDGF receptors, imatinib, modified the inflammatory responses and the expression patterns 
of PDGF-A and PDGF receptors. This supports the concept that in OB, pathways signaled 
through PDGF receptors are involved.  
 
5. Up-regulation of collagen III mRNA associates with development of OB 
We assessed the cells expressing collagen type I and III mRNA during development of OB in 
bronchial allografts. Development of OB was associated with an increase in fibroblasts 
expressing collagen III mRNA. This expression increased parallel with luminal obliteration 
and number of fibroblasts and amount of extracellular matrix in the bronchial wall. 
 
Increase in number of cells expressing collagen I and III genes and enhanced mRNA 
expression by individual cells are both suggested to contribute to pulmonary fibrosis 
(Shahzeidi et al. 1993, Shahzeidi et al. 1994, Zhang et al. 1994). In addition, an increase in 
type III collagen occurs (Vuorio et al. 1989). Elevated levels of the aminoterminal propeptide 
of type III collagen have been detected in BAL fluid of patients with fibrosing alveolitis 
(Lammi et al. 1999), in adult respiratory distress syndrome (Marshall et al. 2000), and in 
pulmonary edema (Chesnutt 1997), predicting poor prognosis. In post-transplant OB, 
excessive deposition of type III collagen in the bronchial submucosa correlates with poor lung 
function (Zheng et al. 1999). We compared the expression of collagen I and III genes and 
found a dominance of type III collagen expression in fibroblasts in the obliterative plug and in 
the bronchial wall of rapidly obliterating allografts. These findings suggest an association 
between increased synthesis and deposition of collagen III and the severity of a disorder. 
 
Collagen biosynthesis can be regulated at transcriptional, post-transcriptional, and 
translational levels (Raghow et al. 1989). Modulation of mRNA stability and translation into 
protein are important mechanisms in determining net collagen production (Adams 1989). 
Various exo- and endogenous factors affect this process (Bateman et al. 1981, McAnulty et al. 
1995). Influx of inflammatory cells releasing cytokines and growth factors, together with the 
action of immunosuppressive agents, has diverse effects on fibroblasts. In bronchial 
allografts, we found upregulation of PDGF-A, TGF-β, and TNF-α (II, III). TGF-β promotes 
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the transcription and stability of procollagen mRNA (Penttinen et al. 1988, Kenyon et al. 
2003), and together with PDGF–A and TNF-α promotes fibroblast replication and chemotaxis 
(Kovacs et al. 1994, Geremias et al. 2004). Glucocorticoids reduce collagen synthesis by 
reducing levels of procollagen mRNA (Oikarinen et al. 1986). In addition, inhibition of the 
mTOR pathway is demonstrated to inhibit collagen mRNA transcription and stability 
(Shegogue et al. 2004). On the other hand, CsA has been shown to promote type III collagen 
transcription (Oleggiani et al. 2000). In our immunosuppressed allografts, histological 
findings and the number of cells producing type I and III collagen mRNA resembled those of 
autografts. Immunosuppression with CsA, everolimus, and MP not only inhibited immune 
activation and fibrogenesis, but probably also affects the transcriptional and translational rate 
of collagen mRNAs in individual cells.  
 
In bronchial autografts, collagen I and III gene expression observed at early time points led to 
minor fibrotic changes. Nonimmunologic injury caused by the heterotopic method may have 
resulted in this. CTGF expression observed in autografts (III) may provide a link between this 
injury and early collagen gene activation, as CTGF can be induced by mechanical stress 
(Schild et al. 2002). Although expression of type I and III collagen mRNA was detectable 
both in autografts and in immunosuppressed allografts, only insignificant pathological 
alterations were evident. An important finding was the unaltered number of cells expressing 
collagen III mRNA.  
 
Quantitation of total collagen and collagen I and III mRNA did not directly correlate with the 
increase in positive cells detected by in situ hybridization. In autografts and 
immunosuppressed allografts, cartilage remained viable and proliferating. Total collagen 
content probably reflected more the changes in the collagen type II derived from cartilage 
than the changes in relatively small fibrotic areas of the bronchial wall or lumina in 
nontreated allografts. Quantification of mRNAs by Northern hybridization does not identify 
the tissue origin of mRNA, and the strong expression of collagen genes in immunosuppressed 
allografts at some assessment points may have been detected in the pericartilaginous area. 
 
In conclusion, this study showed that collagen I and III mRNA were expressed in fibroblasts 
in OB lesions, with a preponderance of and increase in cells expressing type III mRNA. In 
autografts and in allografts with immunosuppression adequate to prevent OB, only a minor 
degree of collagen gene activation occurred. In these groups, no changes in genetic activity 
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between type I and III collagen were observable, in contrast to the situation in obliterating 
allografts.  
 
6. Conclusions 
Transplanted lung may develop OB as a response to alloimmune injury.  In this pathogenic 
process, epithelial cell injury, inflammatory cell invasion, and fibroblast proliferation and 
extracellular matrix accumulation take place. The data in this thesis suggest that these 
pathological changes are associated with increased epithelial cell apoptosis and increased 
production of TNF-α, PDGF, and TGF-β, as well as synthesis of collagen III mRNA. 
 
In bronchial allografts, high apoptotic activity together with changes in epithelial morphology 
and destruction signaled OB development. When immunosuppressive therapy was sufficiently 
effective to prevent epithelial injury, few epithelial cells appeared apoptotic. This indicates 
that increased apoptotic activity in bronchial grafts is caused primarily by alloimmune injury. 
These results support the idea that epithelial cell apoptosis is an important mechanism in the 
events resulting in OB.  
 
This study showed a correlation between increased expression of TNF-α and airway epithelial 
injury and obliteration. Inhibition of TNF-α by infliximab delayed the process of epithelial 
destruction and luminal occlusion, suggesting that TNF-α is a crucial mediator of epithelial 
injury, as well as of inflammatory and fibroproliferative changes in OB. 
 
Up-regulation of PDGF-A, of PDGF receptors, and of TGF-β occurred in rejection of 
bronchial allografts. These findings confirm the contribution of PDGF and TGF-β to OB. An 
agent targeting PDGF receptors, imatinib, modified the expression patterns of PDGF-A and 
PDGF receptors, and had a prominent influence on the number of CD4+ and CD8+ 
lymphocytes, and of macrophages. This indicates the importance for OB development of the 
pathways signaled through PDGF receptors.  
 
Predominance of fibroblasts expressing collagen III mRNA increased parallel to progression 
of bronchial wall fibrosis and luminal obliteration. In autografts and in allografts with 
immunosuppression adequate to prevent OB, only a minor degree of collagen gene activation 
occurred without changes in genetic activity between types I and III collagen. This 
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observation indicates that one of the mechanisms in the fibrotic process of OB is an increase 
in fibroblasts expressing collagen III mRNA.  
 
The studies presented in this thesis provide further understanding of the mechanisms of OB 
and offer insights into future development of treatment options.  
 61
ACKNOWLEDGEMENTS 
 
This study was carried out at the Department of Cardiothoracic Surgery, Helsinki University 
Hospital. I wish to express my sincere gratitude to all my coworkers and friends who have 
helped and encouraged me. Especially I would like to thank: 
 
 
My supervisor Professor Ari Harjula, for providing me the subject of this thesis and the 
possibility to perform this work. His optimism regarding this study never failed, and I will 
always remember his good advice. 
 
 
My supervisor Docent Ulla-Stina Salminen, who guided me through this work. I am grateful 
for those countless hours she spent teaching and working with me. Without her, this study 
would have been impossible. I admire her strong, energetic spirit in science, surgery, and in 
life in general. 
 
 
Docent Paula Maasilta, whose impact was vital for completion of this study. Her knowledge 
of pulmonology and of scientific writing and statistics was invaluable. I am indebted to her 
for the immense amount of work she has put into this study. 
 
 
The reviewers of this work appointed by the Faculty of Medicine, Docents Hannu Jalanko and 
Heikki Mäkisalo, for their kind advice and useful comments. 
 
 
Professor Seppo Meri, Docent Hannu Jalanko, and the late Professor Juhani Ahonen, for good 
advice as my thesis committee members. 
 
 
Docent Tuija Ikonen, for early guidance and advice with this thesis. I am grateful for the 
benefits from spending time with her at Stanford University.  
 
 
My co-authors: Kaija Inkinen; without her vast knowledge of biochemistry and help with the 
laboratory work this study would have been very difficult. She was always willing to help and 
give advice. Docent Eero Taskinen, for teaching me transplant pathology. I will always 
remember his good jokes and stories. Professor Paavo Pääkkö, for help with the apoptosis 
analyses. Professor Eero Vuorio and Virpi Glumoff, for help with the collagen studies. Pekka 
Hämmäinen and Jukka Salminen, for back-upping me in pig surgery. 
 
 
Professor Markku Löytönen, for help with the statistics and figures. 
 
 
Docent Irmeli Lautenschlager and Professor Krister Höckerstedt, for their encouragement and 
interest towards this study. I also thank Docent Lautenschlager for her good advice and 
knowledge in transplantation immunology. 
 62
Sisko Litmanen for her excellent technical assistance and sharing the ups and downs of this 
study.  I remember long hours spent in the laboratory discussing all aspects of life. 
 
 
The young doctors like Timi Martelius, Ilkka Helanterä, Maiju Härmä, and Outi Päiväniemi, 
for their companionship over the past years.  
 
 
Raisa Loginov and Marjatta Palovaara for their help in various practical problems. The staff 
of the Animal Laboratory, especially Pirkko Uhlbäck, for help with the laboratory animals. 
Carol Norris for language editing. 
 
 
My colleagues Minna Kujala-Myllynen and Johanna Savikko, for sharing the joy and agony 
of scientific work. Their support and companionship means a lot to me. 
 
 
My friends Tia, Nina, Virve, Sami, Suvi, Liina, Katariina, Anniina, and Kariina for their 
friendship. 
 
 
My mother Anna-Liisa, my father Kari and, my sister Laura Linnea, for all the love and 
support they have given me. 
 
 
Jarmo, my husband to be, for his love. I cannot find words to thank you enough for supporting 
me and being in my life.  
 
 
This study was financially supported by the Helsinki Biomedical Graduate School, Helsinki 
University Special Funds, Finska Läkaresällskapet, Helsinki Biomedicum Research Funds, 
the Finnish Medical Foundation, Tampereen Tuberkuloosisäätiö, and the Finnish Anti-
Tuberculosis Association Foundation. 
 
 
 
Helsinki, April 2005 
 
 
 
 
Hanni Alho 
 63
REFERENCES 
 
Adams SH. Collagen gene expression. Am J Respir Cell Mol Biol 1989; 1: 161-8. 
 
Adams BF, Brazelton T, Berry GJ, Morris RE. The role of respiratory epithelium in a rat model of obliterative 
airway disease. Transplantation 2000; 69: 661-4. 
 
Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M et al. Cxcr3 and its ligand CXCL10 are expressed 
by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J 
Pathol 2001; 158: 1703-11.  
 
Ala-Kokko L, Kontusaari S, Baldwin CT, Kuivaniemi H, Prockop DJ. Structure of cDNA clones coding for the 
entire preproα1(III) chain of human type III procollagen. Biochem J 1989; 260: 509-16. 
 
Al-Dossari GA, Kshettry VR, Jessurun J and Bolman RM 3rd. Experimental large-animal model of obliterative 
bronchiolitis after lung transplantation. Ann Thorac Surg 1994; 58: 34-9. 
 
Al-Dossari GA, Jessurun J, Bolman RM, 3rd, Kshettry VR, King MB, Murray JJ et al. Pathogenesis of 
obliterative bronchiolitis. Possible roles of platelet-derived growth factor and basic fibroblast growth factor. 
Transplantation 1995; 59: 143-5. 
 
Allan JS, Wain JC, Schwarze ML, Houser SL, Benjamin LC, Madsen JC et al. Modeling chronic lung allograft 
rejection in miniature swine. Transplantation 2002; 73: 447-53. 
 
Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150: 1423-38. 
 
Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 
2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary 
sarcoidosis. Am J Respir Cell Mol Biol 1999; 21: 693-700. 
 
Alpers CE, Davis CL, Barr D, Marsh CL, Hudkins KL. Identification of platelet-derived growth factor A and B 
chains in human renal vascular rejection. Am J Pathol 1996; 148: 439-51. 
 
Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the 
development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 
2004; 103: 538-44. 
 
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate 
in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor 
receptor beta. N Engl J Med 2002; 347: 481-7. 
 
Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer I. Growth factor upregulation during obliterative 
bronchiolitis in the mouse model. Am J Respir Crit Care Med 2002; 166: 417-22. 
 
Aspalter RM, Eibl MM, Wolf HM. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 
2003; 74: 572-82. 
 
Assuncao Guimaraes C, Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J 
Biochem 2004; 271: 1638-50. 
 
Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 
2003; 14: 537-50. 
 
Auchincloss H Jr. Role of graft in transplantation tolerance. Transplantation 1995; 59: 450. 
 
Auchincloss H Jr., Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol 1996; 
8: 681-7. 
 64
Aziz T, Hasleton P, Hann AW, Yonan N, Deiraniya A, Hutchinson IV. Transforming growth factor beta in 
relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg 2000; 119: 700-
8. 
 
Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and 
morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460-6. 
 
Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P et al. Everolimus and mycophenolate mofetil 
are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275-80. 
 
Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion 
and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in 
vivo. Mol Cell Biol 1999; 19: 2958-66. 
 
Bach FH, van Rood JJ. The major histocompatibility complex - genetics and biology (third of three parts). N 
Engl J Med 1976; 295: 927-36. 
 
Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705. 
 
Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler R. Comparison of the direct and indirect 
pathways of allorecognition in chronic allograft failure. Transplant Proc 2001; 33: 449. 
 
Baldwin WM 3rd, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation. 
Contributions to inflammation, injury, and rejection. Transplantation 1995; 59: 797-808. 
 
Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004; 
125: 754-65. 
 
Bateman E, Turner-Warwick M, Adelmann-Grill BC. Immunohistochemical study of collagen types in human 
foetal lung and fibrotic lung disease. Thorax 1981;36:645-53. 
 
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. 
BioDrugs 2003; 17: 425-31. 
 
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25. 
 
Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of 
metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to 
tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant 2001; 20: 1144-51. 
 
Behr J, Maier K, Braun B, Schwaiblmair M, Vogelmeier C. Evidence for oxidative stress in bronchiolitis 
obliterans syndrome after lung and heart-lung transplantation. The Munich Lung Transplant Group. 
Transplantation 2000; 69: 1856-60. 
 
Belperio JA, Keane MP, Burdick MD, Lynch JP, 3rd, Xue YY, Berlin A et al. Critical role for the chemokine 
MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001; 108: 547-56. 
 
Belperio JA, Keane MP, Burdick MD, Lynch JP, 3rd, Xue YY, Li K et al. Critical role for CXCR3 chemokine 
biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169: 1037-49. 
 
Bergmann M, Tiroke A, Schafer H, Barth J, Haverich A. Gene expression of profibrotic mediators in 
bronchiolitis obliterans syndrome after lung transplantation. Scand Cardiovasc J 1998; 32: 97-103. 
 
Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH et al. PDGF-D is a specific, protease-activated 
ligand for the PDGF beta-receptor. Nat Cell Biol 2001; 3: 512-516. 
 65
Bernard MP, Chu M-L, Myers JC, Ramirez F, Eikenberry EF, Prockop DJ. Nucleotide sequences of 
complementary deoxyribonucleic acids for the proα1 chain of human type I procollagen. Statistical evaluation of 
structures that are conserved during evolution. Biochemistry 1983; 22: 5213-23. 
 
Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev 
Biochem 1988;57:505-18. 
 
Bewig B, Stewart S, Bottcher H, Bastian A, Tiroke A, Hirt S et al. Eosinophilic alveolitis in BAL after lung 
transplantation. Transpl Int 1999; 12: 266-72. 
 
Bhorade SM, Jordan A, Villanueva J, Yu A, Kramer H, Vigneswaran WT et al. Comparison of three tacrolimus-
based immunosuppressive regimens in lung transplantation. Am J Transplant 2003; 3: 1570-5. 
 
Bittmann I, Muller C, Behr J, Groetzner J, Frey L, Lohrs U. Fas/FasL and perforin/granzyme pathway in acute 
rejection and diffuse alveolar damage after allogeneic lung transplantation-a human biopsy study. Virchows Arch 
2004; 445: 375-81. 
 
Black JL, Burgess JK, Johnson PR. Airway smooth muscle--its relationship to the extracellular matrix. Respir 
Physiol Neurobiol 2003; 137: 339-46. 
 
Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for 
antifibrotic therapy? Matrix Biol 2002; 21: 473-82. 
 
Boehler A, Bai XH, Liu M, Cassivi S, Chamberlain D, Slutsky AS et al. Upregulation of T-helper 1 cytokines 
and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med 1999; 159: 1910-7. 
 
Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J  2003; 22: 1007-18. 
 
Bolton EM, Armstrong HE, Briggs JD, Bradley JA. Cellular requirements for first-set renal allograft rejection. 
Transplant Proc 1987; 19: 321-3. 
 
Bolton EM, Gracie JA, Briggs JD, Kampinga J, Bradley JA. Cellular requirements for renal allograft rejection in 
the athymic nude rat. J Exp Med 1989; 169: 1931-46. 
 
Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI. Registry for the International Society 
for Heart and Lung Transplantation: seventh official pediatric report - 2004. J Heart Lung Transplant 2004; 23: 
933-47. 
 
Brandt M, Derner G, Boeke K, Phillips ML, Steinhoff G, Haverich A. Anti-rejection prophylaxis by blocking 
selectin dependent cell adhesion after rat allogeneic and xenogeneic lung transplantation. Eur J Cardiothorac 
Surg 1997; 12: 781-6. 
 
Brass DM, Hoyle GW, Poovey HG, Liu JY, Brody AR. Reduced tumor necrosis factor-alpha and transforming 
growth factor-beta1 expression in the lungs of inbred mice that fail to develop fibroproliferative lesions 
consequent to asbestos exposure.  Am J Pathol 1999; 154 :853-62. 
 
Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other 
spondyloarthritides. Expert Opin Investig Drugs 2003; 12: 1097-109. 
 
Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003; 178: 169-75. 
 
Brock MV, Borja MC, Ferber L, Orens JB, Anzcek RA, Krishnan J et al. Induction therapy in lung 
transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and 
daclizumab. J Heart Lung Transplant 2001; 20: 1282-90. 
 
Brody AR, Bonner JC, Overby LH, Badgett A, Kalter V, Kumar RK et al. Interstitial pulmonary macrophages 
produce platelet-derived growth factor that stimulates rat lung fibroblast proliferation in vitro. J Leukoc Biol 
1992; 51: 640-8. 
 66
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor 
STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J 
Pharmacol Exp Ther 2000; 295: 139-45. 
 
Burke CM, Theodore J, Dawkins KD, Yousem SA, Blank N, Billingham ME et al. Post-transplant obliterative 
bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984; 86: 824-9. 
 
Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv 
Immunol 1999; 72: 209-53. 
 
Byers PH. Collagens: building blocks at the end of the development line. Clin Genet 2000; 58: 270-9. 
 
Cahill BC, Somerville KT, Crompton JA, Parker ST, O'Rourke MK, Stringham JC et al. Early experience with 
sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22: 169-
76. 
 
Cantu E 3rd, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R et al. Early fundoplication prevents 
chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78: 1142-
51. 
 
Chabot F, Mitchell JA, Gutteridge JM, Evans TW. Reactive oxygen species in acute lung injury. Eur Respir J 
1998; 11: 745-57. 
 
Chakinala MM, Trulock EP. Acute allograft rejection after lung transplantation: diagnosis and therapy. Chest 
Surg Clin N Am 2003; 13: 525-42. 
 
Chalermskulrat W, Neuringer IP, Brickey WJ, Felix NJ, Randell SH, Ting JP et al. Hierarchical contributions of 
allorecognition pathways in chronic lung rejection. Am J Respir Crit Care Med 2003a; 167: 999-1007. 
 
Chalermskulrat W, Neuringer IP, Schmitz JL, Catellier DJ, Gurka MJ, Randell SH et al. Human leukocyte 
antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. 
Chest 2003b; 123: 1825-31.  
 
Charpin JM, Valcke J, Kettaneh L, Epardeu B, Stern M, Israel-Biet D. Peaks of transforming growth factor-beta 
mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. Transplantation 
1998; 65: 752-5. 
 
Charpin JM, Stern M, Grenet D, Israel-Biet D. Insulinlike growth factor-1 in lung transplants with obliterative 
bronchiolitis. Am J Respir Crit Care Med 2000; 161: 1991-8. 
 
Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung 
injury. Am J Respir Crit Care Med 1997; 156: 840-5. 
 
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-
chloroform extraction. Anal Biochem 1987; 162: 156-9. 
 
Chou DH, Lee W, McCulloch CA. TNF-alpha inactivation of collagen receptors: implications for fibroblast 
function and fibrosis. J Immunol 1996; 156: 4354-62. 
 
Clement MV, Legros-Maida S, Israel-Biet D, Carnot F, Soulie A, Reynaud P et al. Perforin and granzyme B 
expression is associated with severe acute rejection. Evidence for in situ localization in alveolar lymphocytes of 
lung-transplanted patients. Transplantation 1994; 57: 322-6. 
 
Coers W, Van der Bij W, Bij W, Drok G, Timens W. Extracellular matrix composition of obliterated bronchioli 
in lung transplant recipients. Transplant Proc 1999; 31: 191-2. 
 
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial 
cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. Faseb J 1995; 9: 899-909. 
 
Colvin RB. Cellular and molecular mechanisms of allograft rejection. Annu Rev Med 1990; 41: 361-7. 
 67
Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell receptor ligation can determine 
the functional differentiation of naive CD4+ T cells. J Exp Med 1995; 182: 1591-6. 
 
Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J et al. A working formulation for the 
standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International 
Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-6.  
 
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J et al. Infliximab induces potent anti-
inflammatory and local immunomodulatory activity but no systemic immunesuppression in patients with 
Crohn’s disease. Aliment Pharmacol Ther 2001; 15: 463-73. 
 
Crim C, Keller CA, Dunphy CH, Maluf HM, Ohar JA. Flow cytometric analysis of lung lymphocytes in lung 
transplant recipients. Am J Respir Crit Care Med 1996; 153: 1041-6. 
 
Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation 
and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-9. 
 
Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of MHC Class II antigens in 
normal human organs. Transplantation 1984; 38: 293-8. 
 
Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the 
profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 
1308-16. 
 
Daynes RA, Dowell T, Araneo BA. Platelet-derived growth factor is a potent biologic response modifier of T 
cells. J Exp Med 1991; 174: 1323-33. 
 
de Groot-Kruseman HA, Mol WM, Niesters HG, Maat AP, van Gelder T, Balk AH et al. Differential intragraft 
cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. 
Transpl Int 2003; 16: 9-14. 
 
Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular 
mechanisms of apoptosis. Ann N Y Acad Sci 2003; 1010: 1-8. 
 
DeMeester SR, Rolfe MW, Kunkel SL, Swiderski DL, Lincoln PM, Deeb GM et al. The bimodal expression of 
tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection. J Immunol 1993: 
150; 2494-505. 
 
DeMeo DL, Ginns LC. Clinical status of lung transplantation. Transplantation 2001a; 72: 1713-24. 
 
DeMeo DL, Ginns LC. Lung transplantation at the turn of the century. Annu Rev Med 2001b; 52: 185-201. 
 
Demirci G, Nashan B, Pichlmayr R. Fibrosis in chronic rejection of human liver allografts: expression patterns 
of transforming growth factor-TGFbeta1 and TGF-beta3. Transplantation 1996; 62: 1776-83. 
 
Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Biophys Acta 1997; 1333: F105-50. 
 
De Soyza A, Fisher AJ, Small T, Corris PA. Inhaled corticosteroids and the treatment of lymphocytic 
bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001; 164: 1209-12. 
 
De Vito Dabbs A, Dauber JH, Hoffman LA. Rejection after organ transplantation: a historical review. Am J Crit 
Care 2000; 6: 419-29. 
 
Devouassoux G, Pison C, Drouet C, Pin I, Brambilla C, Brambilla E. Early lung leukocyte infiltration, HLA and 
adhesion molecule expression predict chronic rejection. Transpl Immunol 2001; 8: 229-36. 
 
Diamond DA, Michalski JM, Lynch JP, Trulock EP 3rd. Efficacy of total lymphoid irradiation for chronic 
allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 1998; 41: 795-800. 
 68
Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell 
proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094-9.  
 
DiGiovine B, Lynch JP 3rd, Martinez FJ, Flint A, Whyte RI, Iannettoni MD et al. Bronchoalveolar lavage 
neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 1996; 
157: 4194-202. 
 
Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L et al. Defective mucosal T cell 
death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-
7. 
 
Dosanjh AK, Elashoff D, Kawalek A, Moss RB, Esrig S. Activation of eosinophils in the airways of lung 
transplantation patients. Chest 1997; 112: 1180-3. 
 
Dosanjh AK, Robinson TE, Strauss J, Berry G. Eosinophil activation in cardiac and pulmonary acute allograft 
rejection. J Heart Lung Transplant 1998; 17: 1038. 
 
Dosanjh A, Ikonen T, Morris R. Respiratory epithelial expression of integrin alphaVbeta6 in chronic progressive 
allograft rejection. J Heart Lung Transplant 2004; 23: 456-60.  
 
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor 
of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.  N Engl J Med 2001; 344:1031-7. 
 
Duncan SR, Valentine V, Roglic M, Elias DJ, Pekny KW, Theodore J et al. T cell receptor biases and clonal 
proliferations among lung transplant recipients with obliterative bronchiolitis. J Clin Invest 1996; 97: 2642-50. 
 
Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans 
syndrome in lung transplant recipients. J Heart Lung Transplant 1996; 15: 948-54. 
 
Eerola L, Alho HS, Maasilta PK, Harjula ALJ, Inkinen KA, Litmanen S, Salminen US. Matrix metalloproteinase 
induction in post-transplant obliterative bronchiolitis. J Heart Lung Transplant  2005; 24: 426-32.  
 
Eidelman O, Srivastava M, Zhang J, Leighton X, Murtie J, Jozwik C et al. Control of the proinflammatory state 
in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Mol Med 2001; 7: 
523-34. 
 
El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J et al. Transforming growth factor-beta1 and lung 
allograft fibrosis. Eur J Cardiothorac Surg 1998; 13: 424-30. 
 
El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J et al. Transforming growth factor beta (TGF-
beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828-
37. 
 
Elssner A, Jaumann F, Dobmann S, Behr J, Schwaiblmair M, Reichenspurner H et al. Elevated levels of 
interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with 
bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant 
Group. Transplantation 2000; 70: 362-7. 
 
Elssner A, Vogelmeier C. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung 
transplantation. Transpl Infect Dis 2001; 3: 168-76. 
 
Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L. In situ localization of TNFalpha/beta, 
TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine 2003; 22: 89-
100. 
 
Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M et al. Bronchiolitis obliterans syndrome 2001: an 
update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310. 
 69
Evans PC, Smith S, Hirschfield G, Rigopoulou E, Wreghitt TG, Wight DG et al. Recipient HLA-DR3, tumour 
necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated 
risk factors for chronic rejection of liver grafts. J Hepatol 2001; 34: 711-5. 
 
Farivar AS, Krishnadasan B, Naidu BV, Woolley SM, Mulligan MS. The role of the beta chemokines in 
experimental obliterative bronchiolitis. Exp Mol Pathol 2003; 75: 210-6. 
 
Farivar AS, Mackinnon-Patterson B, Woolley S, Namkung J, Shimamoto A, Verrier ED et al. FR167653 reduces 
obliterative airway disease in rats. J Heart Lung Transplant 2004a; 23: 985-92. 
 
Farivar AS, Woolley SM, Naidu BV, Fraga CH, Byrne K, Thomas R et al. Poly (ADP) ribose synthetase 
inhibition reduces obliterative airway disease in rat tracheal allografts. J Heart Lung Transplant 2004b; 23: 993-
1002. 
 
Fattal-German M, Le Roy Ladurie F, Lecerf F, Berrih-Aknin S. Expression of ICAM-1 and TNF alpha in human 
alveolar macrophages from lung-transplant recipients. Ann N Y Acad Sci 1996; 796: 138-48. 
 
Fattal-German M, Le Roy Ladurie F, Cerrina J, Lecerf F, Berrih-Aknin S. Expression and modulation of ICAM-
1, TNF-alpha and RANTES in human alveolar macrophages from lung-transplant recipients in vitro. Transpl 
Immunol 1998; 6: 183-92. 
 
Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G. De novo autoimmunity to cardiac myosin 
after heart transplantation and its contribution to the rejection process. J Immunol 1999; 162: 6836-42.  
 
Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid 
arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant 
Proc 1998; 30: 4126-7. 
 
Feldman M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev 
Immunol 2001: 19; 163-6. 
 
Fellström B, Klareskog L, Heldin CH, Larsson E, Ronnstrand L, Terracio L et al. Platelet-derived growth factor 
receptors in the kidney - upregulated expression in inflammation. Kidney Int 1989; 36: 1099-102. 
 
Fischer S, Cassivi SD, Xavier AM, Cardella JA, Cutz E, Edwards V et al. Cell death in human lung 
transplantation: apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg 2000a; 
231: 424-31. 
 
Fischer S, Maclean AA, Liu M, Cardella JA, Slutsky AS, Suga M et al. Dynamic changes in apoptotic and 
necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation. Am J Respir 
Crit Care Med 2000b; 162: 1932-9. 
 
Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR et al. Ischemia-reperfusion injury after lung 
transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73: 1041-7. 
 
Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels 
following lung transplantation. Thorax 1998; 53: 454-8. 
 
Floege J, Hudkins KL, Davis CL, Schwartz SM, Alpers CE. Expression of PDGF alpha-receptor in renal 
arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 1998; 9: 211-23. 
 
Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110: 559-62. 
 
Gaston RS, Deierhoi MH, Ayres I. HLA matching in renal transplantation. N Engl J Med 1995; 332: 752-3.  
 
Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. 
Biochem Pharmacol 2003; 66: 1403-8. 
 70
Genovese C, Rowe D, Kream B. Construction of cDNA sequences complementary to rat (1 and (2 collagen 
mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. 
Biochemistry 1984; 23: 6210-6. 
 
George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 
2003; 532: 141-51. 
 
Geremias AT, Carvalho MA, Borojevic R, Monteiro AN. TGF beta1 and PDGF AA override Collagen type I 
inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol 2004; 4: 30. 
 
Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp 
Biol Med 2002; 227: 301-14. 
 
Glumoff V, Mäkelä JK, Vuorio E. Cloning of cDNA for rat pro alpha 1(III) collagen mRNA. Different 
expression patterns of type I and III collagen and fibronectin genes in experimental granulation tissue. Biochim 
Biophys Acta 1994; 1217: 41-8. 
 
Gu Y, Takao M, Kai M, Lu L, Shimamoto A, Onoda K et al. The role of cyclosporine A and interleukin-2 in 
obliterative airway disease in a rat tracheal transplant model. Ann Thorac Cardiovasc Surg 2000; 6: 224-31. 
 
Hamlin CR, Kohn RR. Evidence for progressive, age-related structural changes in post-mature human collagen. 
Biochim Biophys Acta 1971; 236: 458-67. 
 
Hancock WH, Whitley WD, Tullius SG, Heemann UW, Wasowska B, Baldwin WM 3rd et al. Cytokines, 
adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 
643-50. 
 
Hansen PR, Holm AM, Svendsen UG, Olsen PS, Andersen CB. Apoptosis in acute pulmonary allograft rejection 
and cytomegalovirus infection. Apmis 1999; 107: 529-33. 
 
Hansen PR, Holm AM, Svendsen UG, Olsen PS, Andersen CB. Apoptosis and formation of peroxynitrite in the 
lungs of patients with obliterative bronchiolitis. J Heart Lung Transplant 2000; 19: 160-6. 
 
Haque MA, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, Zheng Y et al. Evidence for immune 
responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of 
lung allograft rejection. J Immunol 2002; 169: 1542-9. 
 
Hardy JD, Webb WR, Dalton ML Jr., Walker GR Jr. Lung Homotransplantation in Man. Jama 1963; 186: 1065-
74.  
 
Harjula AL, Baldwin JC, Glanville AR, Tazelaar H, Oyer PE, Stinson EB, Shumway NE. Human leukocyte 
antigen compatibility in heart-lung transplantation. J Heart Transplant 1987; 6: 162-6. 
 
Hausen B, Berry GJ, Dagum P, Ikonen T, Christians U, Briffa N et al. The histology of subcutaneously 
implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant 
model. J Heart Lung Transplant 1999; 18: 714-24. 
 
Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC et al. Combined immunosuppression with 
cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-
based trials to improve efficacy and tolerability. Transplantation 2000a; 69: 76-86.  
 
Hausen B, Boeke K, Berry GJ, Christians U, Schuler W, Morris RE. Successful treatment of acute, ongoing rat 
lung allograft rejection with the novel immunosuppressant SDZ-RAD. Ann Thorac Surg 2000b; 69: 904-9. 
 
Hayashi M, Martinez OM, Garcia-Kennedy R, So S, Esquivel CO, Krams SM. Expression of cytokines and 
immune mediators during chronic liver allograft rejection. Transplantation 1995; 60: 1533-8. 
 
Heeger PS. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003; 3: 
525-33. 
 71
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase 
activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-32. 
 
Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 
1999; 79: 1283-316. 
 
Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch 
Biochem Biophys 2002; 398: 284-90. 
 
Hele DJ, Yacoub MH, Belvisi MG. The heterotopic tracheal allograft as an animal model of obliterative 
bronchiolitis. Respir Res 2001; 2: 169-83. 
 
Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: 
incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255-63. 
 
Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JM et al. Obliterative bronchiolitis after 
lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad 
Sci U S A 1992; 89: 10385-9. 
 
Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after 
heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945-51. 
 
Higenbottam T, Stewart S, Penketh A, Wallwork J. Transbronchial lung biopsy for the diagnosis of rejection in 
heart-lung transplant patients. Transplantation 1988; 46: 532-9. 
 
Hirabayashi T, Demertzis S, Schafers J, Hoshino K, Nashan B. Chronic rejection in lung allografts: 
immunohistological analysis of fibrogenesis. Transpl Int 1996; 9 Suppl 1: S293-5. 
 
Hirsch J, Elssner A, Mazur G, Maier KL, Bittmann I, Behr J et al. Bronchiolitis obliterans syndrome after  
(heart-) lung transplantation. Impaired antiprotease defense and increased oxidant activity. Am J Respir Crit 
Care Med 1999; 160: 1640-6.  
 
Hirt SW, You XM, Moller F, Boeke K, Starke M, Spranger U et al. Development of obliterative bronchiolitis 
after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. J Heart 
Lung Transplant 1999; 18: 542-8. 
 
Holland VA, Cagle PT, Windsor NT, Noon GP, Greenberg SD, Lawrence EC. Lymphocyte subset populations 
in bronchiolitis obliterans after heart-lung transplantation. Transplantation 1990; 50: 955-9. 
 
Holtmann MH, Neurath MF. Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 2004; 
4: 439-44. 
 
Hosenpud JD, Edwards EB, Lin HM, Daily OP. Influence of HLA matching on thoracic transplant outcomes. An 
analysis from the UNOS/ISHLT Thoracic Registry. Circulation 1996; 94: 170-4. 
 
Hruban RH, Beschorner WE, Baumgartner WA, Achuff SC, Traill TA, Marsh BR et al. Diagnosis of lung 
allograft rejection by bronchial intraepithelial Leu-7 positive T lymphocytes. J Thorac Cardiovasc Surg 1988; 
96: 939-46. 
 
Hsu RB, Tsay YG, Lee CM, Chen RJ, Wang SS, Chu SH. Soluble inflammatory markers in coronary sinus and 
peripheral blood of heart transplant recipients. Clin Transplant 2003; 17: 331-7. 
 
Huang X, Reichenspurner H, Shorthouse R, Cao W, Berry G, Morris R. Heterotopic tracheal allograft 
transplantation: a new model to study the cellular and molecular events causing obliterative airway disease 
(OAD) in rats. J Heart Lung Transplant 1995; 14: S49. 
 
Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL et al. Aerosolized cyclosporine in 
lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996; 153: 1451-5. 
 72
Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene 
expression in human skin fibroblasts and during wound repair. Mol Cell Biol 1993; 4: 637-45. 
 
Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14: 681-5. 
 
Ikonen T, Taskinen E, Uusitalo M, Aarnio P, Hayry P, Harjula AL. Chronic vascular changes and obliterative 
bronchiolitis in an experimental porcine lung transplantation model. Transplant Proc 1995; 27: 2117. 
 
Ikonen T, Kivisaari L, Harjula AL, Lehtola A, Heikkila L, Kinnula VL et al. Value of high-resolution computed 
tomography in routine evaluation of lung transplantation recipients during development of bronchiolitis 
obliterans syndrome. J Heart Lung Transplant 1996; 15: 587-95. 
 
Ikonen T, Kivisaari L, Taskinen E, Uusitalo M, Aarnio P, Harjula ALJ. Acute rejection diagnosed with 
computed tomography in a porcine experimental lung transplantation model. 
Scand Cardiovasc J 1997; 31: 25-32.  
 
Ikonen T, Uusitalo M, Taskinen E, Korpela A, Salminen US, Morris RE et al. Small airway obliteration in a new 
swine heterotopic lung and bronchial allograft model. J Heart Lung Transplant 1998; 17: 945-53. 
 
Ikonen TS, Brazelton TR, Berry GJ, Shorthouse RS, Morris RE. Epithelial re-growth is associated with 
inhibition of obliterative airway disease in orthotopic tracheal allografts in non-immunosuppressed rats. 
Transplantation 2000; 70: 857-63. 
 
Illigens BM, Yamada A, Fedoseyeva EV, Anosova N, Boisgerault F, Valujskikh A et al. The relative 
contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends 
upon the nature of the transplant. Hum Immunol 2002; 63: 912-25. 
 
Inaki N, Tsunezuka Y, Kawakami K, Sato H, Takino T, Oda M et al. Increased matrix metalloproteinase-2 and 
membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine 
tracheas. J Heart Lung Transplant 2004; 23: 218-27. 
 
Ito H, Kasagi N, Shomori K, Osaki M, Adachi H. Apoptosis in the human allografted kidney. Analysis by 
terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 1995; 60: 794-8. 
 
Izbicki G, Shitrit D, Aravot D, Sulkes J, Saute M, Sahar G et al. Improved survival after lung transplantation in 
patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. Transplant 
Proc 2002; 34: 3258-9. 
 
Jaramillo A, Smith MA, Phelan D, Sundaresan S, Trulock EP, Lynch JP et al. Development of ELISA-detected 
anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with 
progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155-61. 
 
Jaramillo A, Naziruddin B, Zhang L, Reznik SI, Smith MA, Aloush AA et al. Activation of human airway 
epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for 
bronchiolitis obliterans syndrome. Transplantation 2001; 71: 966-76. 
 
Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody 
binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a 
possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64: 521-9. 
 
Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC. Activation-dependent adhesion of human platelets 
to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3). J Biol 
Chem 1999; 274: 24321-7. 
 
Jeppsson A, Tazelaar HD, Miller VM, McGregor CG. Distribution of endothelin-1 in transplanted human lungs. 
Transplantation 1998; 66: 806-9. 
 
Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function 
and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-8. 
 73
Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16: 137-45.  
 
Joseph SB, Miner KT, Croft M. Augmentation of naive, Th1 and Th2 effector CD4 responses by IL-6, IL-1 and 
TNF. Eur J Immunol 1998; 28: 277-89.  
 
Kabelitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 65: 869-75. 
 
Kallio EA, Koskinen PK, Aavik E, Vaali K, Lemstom KB. Role of nitric oxide in experimental obliterative 
bronchiolitis (chronic rejection) in the rat. J Clin Invest 1997; 100: 2984-94. 
 
Kallio EA, Koskinen PK, Aavik E, Buchdunger E, Lemstrom KB. Role of platelet-derived growth factor in 
obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med 1999; 160: 1324-32. 
 
Kallio EA, Lemstrom KB, Hayry PJ, Ryan US, Koskinen PK. Blockade of complement inhibits obliterative 
bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med 2000; 161: 1332-9.  
 
Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha 
monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J 
Rheumatol 2000; 27: 841-50. 
 
Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H et al. Cytomegalovirus serologic 
status and postoperative infection correlated with risk of developing chronic rejection after pulmonary 
transplantation. Transplantation 1991; 51: 433-8. 
Kelly K, Hertz MI. Obliterative bronchiolitis. Clin Chest Med 1997; 18: 319-38. 
Kenyon NJ, Ward RW, McGrewG, Last JA. TGF-β1 causes airway fibrosis and increased collagen I and III 
mRNA in mice. Thorax 2003; 58: 772-7. 
Keshavjee S, Zhang XM, Fischer S, Liu M. Ischemia reperfusion-induced dynamic changes of protein tyrosine 
phosphorylation during human lung transplantation. Transplantation 2000; 70: 525-31. 
Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in 
different organisms. Genes Dev 1994; 8: 133-46. 
Kirk JME, Heard BE, Kerr I, Turner-Warwick M, Laurent GJ. Quantitation of types I and III collagen in biopsy 
lung samples from patients with cryptogenic fibrosing alveolitis. Collagen Rel Res 1984; 4: 169-182. 
 
Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 
2004; 23: 159-71. 
 
Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models 
of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 
1999; 169: 175-94. 
 
Koskinen PK, Kallio EA, Krebs R, Lemstrom KB. A dose-dependent inhibitory effect of cyclosporine A on 
obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med 1997; 155: 303-12. 
 
Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. Faseb J 1994; 8: 854-61. 
 
Krams SM, Egawa H, Quinn MB, Villanueva JC, Garcia-Kennedy R, Martinez OM. Apoptosis as a mechanism 
of cell death in liver allograft rejection. Transplantation 1995; 59: 621-5. 
 
Krettek A, Östergren-Lundel G, Fager G, Rosmond C, Bondjers G, Lustig F. Expression of PDGF receptors and 
ligand-induced migration of partially different human monocyte-derived macrophages. Influence of IFN-γ and 
TGF-β. Atherosclerosis 2001; 156: 267-75. 
 
Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. Faseb 
J 1995; 9: 1277-87. 
 74
Kulmatycki KM, Abouchehade K, Sattari S, Jamali F. Drug-disease interaction: reduced β-adrenergic and 
potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions 
in the rat. Brit J Pharm 2001; 133: 286-94. 
 
Laguens RP, Meckert PM, Martino JS, Perrone S, Favaloro R. Identification of programmed cell death 
(apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute 
rejection episodes. J Heart Lung Transplant 1996; 15: 911-8. 
 
Laine J, Etelamaki P, Holmberg C, Dunkel L. Apoptotic cell death in human chronic renal allograft rejection. 
Transplantation 1997; 63: 101-5. 
 
Lammi L, Ryhänen L, Lakari E, Risteli J, Pääkkö P, Kahlos K et al. Type III and type I procollagen markers in 
fibrosing alveolitis. Am J Respir Crit Care Med 1999;159:818-23. 
 
Lee ES, Gotway MB, Reddy GP, Golden JA, Keith FM, Webb WR. Early bronchiolitis obliterans following lung 
transplantation: accuracy of expiratory thin-section CT for diagnosis. Radiology 2000; 216: 472-7. 
 
Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73: 
1373-81. 
 
Leonard CT, Soccal PM, Singer L, Berry GJ, Theodore J, Holt PG et al. Dendritic cells and macrophages in lung 
allografts: A role in chronic rejection? Am J Respir Crit Care Med 2000; 161: 1349-54. 
 
Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M et al. PDGF-C is a new protease-activated ligand 
for the PDGF alpha-receptor. Nat Cell Biol 2000; 2: 302-9. 
 
Linsenmeyer TF. Collagens. In: Hay ED, ed. Cell Biology of Extracellular matrix. New York: Plenum Press, 
1991:7. 
 
Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 
1993; 11: 191-212. 
 
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and 
methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis 
with Concomitant Therapy Study Group. N Engl J Med 2000: 343; 1594-602. 
 
Liu M, Suga M, Maclean AA, St George JA, Souza DW, Keshavjee S. Soluble transforming growth factor-beta 
type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of Bronchiolitis obliterans. 
Am J Respir Crit Care Med 2002; 165: 419-23. 
 
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian 
biology. Cell 2001; 104: 487-501. 
 
Lu KC, Jaramillo A, Mendeloff EN, Huddleston CB, Sweet SC, Patterson GA et al. Concomitant allorecognition 
of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with 
bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 35-43. 
 
Maasilta P, Salminen US, Taskinen E, Hietala EM, Ikonen T, Harjula A. Obliterative airway disease in a porcine 
heterotopic bronchial allograft model. Transpl Int 2000; 13: 218-24. 
 
Maasilta PK, Salminen US, Lautenschlager IT, Taskinen EI, Harjula AL. Immune cells and immunosuppression 
in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2001; 72: 998-1005.  
 
Maasilta PK, Vainikka TLS, Alho HS, Salminen US. Immune cells in a heterotopic lamb-to-pig bronchial 
xenograft model. Submitted.  
 
MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002; 135: 855-75. 
 75
Maclean AA, Liu M, Fischer S, Suga M, Keshavjee S. Targeting the angiotensin system in posttransplant airway 
obliteration: the antifibrotic effect of angiotensin converting enzyme inhibition. Am J Respir Crit Care Med 
2000; 162: 310-5. 
 
Magnan A, Mege JL, Reynaud M, Thomas P, Capo C, Garbe L et al. Monitoring of alveolar macrophage 
production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal 
lung transplantation group. Am J Respir Crit Care Med 1994: 150; 684-9. 
 
Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M et al. Balance between alveolar macrophage IL-
6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir 
Crit Care Med 1996; 153: 1431-6. 
 
Magro CM, Deng A, Pope-Harman A, Waldman WJ, Bernard Collins A, Adams PW et al. Humorally mediated 
posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a 
hypothesis. Transplantation 2002; 74: 1273-80. 
 
Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM et al. Anti-tumour necrosis factor specific 
antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum 
Dis 1999;58 (Suppl):156-60. 
 
Mancini MC, Evans JT. Role of platelet-derived growth factor in allograft vasculopathy. Ann Surg 2000; 231: 
682-8. 
 
Mares DC, Heidler KM, Smith GN, Cummings OW, Harris ER, Foresman B et al. Type V collagen modulates 
alloantigen-induced pathology and immunology in the lung. Am J Respir Cell Mol Biol 2000; 23: 62-70. 
 
Marshall RP, Bellingan G, Webb S, Puddicombe A, Goldsack N, McAnulty RJ et al. Fibroproliferation occurs 
early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med 2000; 162: 
1783-8. 
 
Martelius T, Scholz M, Krogerus L, Hockerstedt K, Loginov R, Bruggeman C et al. Antiviral and 
immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection. 
Transplantation 1999; 68: 1753-61. 
 
Mason NA, Springall DR, Pomerance A, Evans TJ, Yacoub MH, Polak JM. Expression of inducible nitric oxide 
synthase and formation of peroxynitrite in posttransplant obliterative bronchiolitis. J Heart Lung Transplant 
1998; 17: 710-4. 
 
Mauck KA, Hosenpud JD. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung 
transplantation. J Heart Lung Transplant 1996; 15: 709-14. 
 
McAnulty RJ, Laurent GJ. Collagen and its regulation in pulmonary fibrosis. In: Phan SH, Thrall RS, editors. 
Pulmonary fibrosis. New York: Marcel Dekker, Inc.; 1995,  p. 135-71. 
 
McDermott CD, Gavita SM, Shennib H, Giaid A. Immunohistochemical localization of nitric oxide synthase and 
the oxidant peroxynitrite in lung transplant recipients with obliterative bronchiolitis. Transplantation 1997; 64: 
270-4. 
 
McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. 
Transplantation 2000; 69: 319-26. 
 
Metsäranta M, Toman D, de Crombrugghe B, Vuorio E. Specific hybridization probes for mouse type I, II, III, 
and IX collagen mRNAs. Biochim Biophys Acta 1991; 1089: 241-3. 
 
Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J 
Biochem Cell Biol 2004; 36: 1031-7. 
 
Milne DS, Gascoigne A, Wilkes J, Sviland L, Ashcroft T, Pearson AD et al. The immunohistopathology of 
obliterative bronchiolitis following lung transplantation. Transplantation 1992; 54: 748-50. 
 76
Milne DS, Gascoigne AD, Wilkes J, Sviland L, Ashcroft T, Malcolm AJ et al. MHC class II and ICAM-1 
expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 
1994; 57: 1762-6. 
 
Minamoto K, Pinsky DJ. Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal 
allografts. J Exp Med 2002; 196: 1321-33. 
 
Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA et al. Expression of a tumor necrosis factor-
alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive 
pulmonary fibrosis. J Clin Invest 1995; 96: 250-9. 
 
Mogayzel PJ, Jr., Yang SC, Wise BV, Colombani PM. Eosinophilic infiltrates in a pulmonary allograft: a case 
and review of the literature. J Heart Lung Transplant 2001; 20: 692-5. 
 
Mora BN, Boasquevisque CH, Boglione M, Ritter JM, Scheule RK, Yew NS et al. Transforming growth factor-
beta1 gene transfer ameliorates acute lung allograft rejection. J Thorac Cardiovasc Surg 2000; 119: 913-20. 
 
Morikawa M, Brazelton TR, Berry GJ, Morris RE. Prolonged inhibition of obliterative airway disease in murine 
tracheal allografts by brief treatment with anti-leukocyte function-associated antigen-1 (CD11a) monoclonal 
antibody. Transplantation 2001; 71: 1616-21.  
 
Morisaki N, Takahashi K, Shiina R, Zenibayashi M, Otabe M, Yoshida S et al. Platelet-derived growth factor is 
a potent stimulator of expression of intercellular adhesion molecule-1 in human arterial smooth muscle cells. 
Biochem Biophys Res Commun 1994; 200: 612-8. 
 
Moussad EEA, Brigstock DR. Connective tissue growth factor: What’s in a name? Mol Genet Metab 2000; 71: 
276-92. 
 
Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001; 33: 7-21. 
 
Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55. 
 
Naidu BV, Farivar AS, Krishnadasan B, Woolley SM, Grainger DJ, Verrier ED et al. Broad-spectrum 
chemokine inhibition ameliorates experimental obliterative bronchiolitis. Ann Thorac Surg 2003; 75: 1118-22. 
 
Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R et al. Antiproliferative effect of 
rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for 
prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29: 614-5. 
 
Neuringer IP, Mannon RB, Coffman TM, Parsons M, Burns K, Yankaskas JR et al. Immune cells in a mouse 
airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol 1998; 19: 379-86. 
 
Neuringer IP, Walsh SP, Mannon RB, Gabriel S, Aris RM. Enhanced T cell cytokine gene expression in mouse 
airway obliterative bronchiolitis. Transplantation 2000; 69: 399-405. 
 
Neuringer IP, Aris RM, Burns KA, Bartolotta TL, Chalermskulrat W, Randell SH. Epithelial kinetics in mouse 
heterotopic tracheal allografts. Am J Transplant 2002; 2: 410-9. 
 
Nguyen DM, Mulder DS, Shennib H. Lectin-dependent cell-mediated cytotoxicity and natural killer function in 
rejecting and infected lung allografts. Transplantation 1993; 55: 1250-6. 
 
Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP et al. Comprehensive gene expression 
profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad 
Sci U S A 2004; 101: 14895-900. 
 
Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M et al. Human connective tissue growth factor is 
expressed in advanced atherosclerotic lesions. Circulation 1997; 95: 831-9. 
 
O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis 
obliterans complicating lung transplantation. Chest 1999; 115: 1459-62. 
 77
Oikarinen AI, Uitto J, Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanisms to 
clinical practice. Med Biol 1986;64:221-30. 
 
Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 
2001; 97: 2440-8. 
 
Oleggiani R, Musante L, Menoni S, Botti G, Duca MD, Prudenziati M et al. Characterization of a DNA binding 
site that mediates the stimulatory effect of cyclosporin-A on type III collagen expression in renal cells. Nephrol 
Dial Transplant 2000;15:778-785. 
 
Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus –induced 
thrombus formation, intraneural edema, and reduction of nerve conduction velocity. Spine 2001; 26: 863-9. 
 
Oyaizu T, Okada Y, Shoji W, Matsumura Y, Shimada K, Sado T et al. Reduction of recipient macrophages by 
gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal 
transplantation. Transplantation 2003; 76: 1214-20. 
 
Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 
673-83. 
 
Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE et al. Development of an antibody 
specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated 
with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799-804. 
 
Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H et al. Type II alveolar epithelial cells and 
interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17: 1220-7. 
 
Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin 
Chest Med 1993; 14: 751-63. 
 
Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002; 7: d1743-61. 
 
Pascher A, Radke C, Dignass A, Schulz RJ, Veltzke-Schlieker W, Adler A, Sauer IM, Platz K, Klupp J, Volk 
HD, Neuhaus P, Mueller AR. Succesful infliximab treatment of steroid and OKT3 refractory acute cellular 
rejection in two patients after intestinal transplantation. Transplantation 2003; 76: 615-8. 
 
Penttinen RP, Kobayashi S, Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins 
both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci U S A 1988; 85: 1105-
8. 
 
Pober JS, Collins T, Gimbrone MA, Jr., Libby P, Reiss CS. Inducible expression of class II major 
histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation 1986; 
41: 141-6. 
 
Päiväniemi OE, Maasilta PK, Alho HS, Wolff CH, Salminen US. Cyclooxygenase-2 expression in experimental 
post-transplant obliterative bronchiolitis. J Pathol 2004; 204: 340-8. 
 
Qin L, Chavin KD, Ding Y, Woodward JE, Favaro JP, Lin J et al. Gene transfer for transplantation. Prolongation 
of allograft survival with transforming growth factor-beta 1. Ann Surg 1994; 220: 508-18. 
 
Radio S, Wood S, Wilson J, Lin H, Winters G, McManus B. Allograft vascular disease: comparison of heart and 
other grafted organs. Transplant Proc 1996; 28: 496-9. 
 
Raghow R, Thompson JP. Molecular mechanisms in collagen gene expression. Mol Cell Biochem 1989;86:5-18.  
 
Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. Am Rev 
Respir Dis 1995; 131: 281-289. 
 78
Ramirez AM, Takagawa S, Sekosan M, Jaffe HA, Varga J, Roman J. Smad3 deficiency ameliorates 
experimental obliterative bronchiolitis in a heterotopic tracheal transplantation model. Am J Pathol 2004; 165: 
1223-32. 
 
Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30. 
 
Reichenspurner H, Girgis RE, Robbins RC, Conte JV, Nair RV, Valentine V et al. Obliterative bronchiolitis after 
lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845-53. 
 
Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI. Are multiple immunopathogenetic events occurring 
during the development of obliterative bronchiolitis and acute rejection? Transplantation 1993; 55: 1040-4. 
 
Reynaud-Gaubert M, Thomas P, Badier M, Cau P, Giudicelli R, Fuentes P. Early detection of airway 
involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell 
findings. Am J Respir Crit Care Med 2000; 161: 1924-9. 
 
Reynaud-Gaubert M, Marin V, Thirion X, Farnarier C, Thomas P, Badier M et al. Upregulation of chemokines 
in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung 
Transplant 2002; 21: 721-30. 
 
Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to hla 
class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis 
obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119: 39-45. 
 
Reznik SI, Jaramillo A, SivaSai KS, Womer KL, Sayegh MH, Trulock EP et al. Indirect allorecognition of 
mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. 
Am J Transplant 2001; 1: 228-35. 
 
Richards DM, Dalheimer SL, Hertz MI, Mueller DL. Trachea allograft class I molecules directly activate and 
retain CD8+ T cells that cause obliterative airways disease. J Immunol 2003; 171: 6919-28. 
 
Riise GC, Schersten H, Nilsson F, Ryd W, Andersson BA. Activation of eosinophils and fibroblasts assessed by 
eosinophil cationic protein and hyaluronan in BAL. Association with acute rejection in lung transplant 
recipients. Chest 1996; 110: 89-96. 
 
Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome 
in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in 
the lung. Eur Respir J 1998; 12: 82-8. 
 
Riise GC, Andersson BA, Kjellstrom C, Martensson G, Nilsson FN, Ryd W et al. Persistent high BAL fluid 
granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur 
Respir J 1999; 14: 1123-30. 
 
Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J et al. Regulation of connective tissue growth 
factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J 
Am Soc Nephrol 2000; 11: 25-38. 
 
Rivo J, Zeira E, Galun E, Matot I. Activation of a adenosine receptor provides lung protection against ischemia-
reperfusion injury associated with reduction in apoptosis. Am J Transplant 2004; 4: 1941-8. 
 
Rizzo M, SivaSai KS, Smith MA, Trulock EP, Lynch JP, Patterson GA et al. Increased expression of 
inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients 
with acute rejection: decline with resolution of rejection. J Heart Lung Transplant 2000; 19: 858-65. 
 
Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858-62. 
 
Rocha PN, Plumb TJ, Crowley SD, Coffman TM. Effector mechanisms in transplant rejection. Immunol Rev 
2003; 196: 51-64. 
 
Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1: 97-102. 
 79
Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94. 
 
Romanska HM, Ikonen TS, Bishop AE, Morris RE, Polak JM. Up-regulation of inducible nitric oxide synthase 
in fibroblasts parallels the onset and progression of fibrosis in an experimental model of post-transplant 
obliterative airway disease. J Pathol 2000; 191: 71-7. 
 
Ross M, Caliguiri M. Cytokine-induced apoptosis of human natural killer cell identifies a novel mechanism to 
regulate the innate immune response. Blood 1999; 89: 910-8. 
 
Roth-Eichhorn S, Schade I, Kasper M, Ploetze K, Wunderlich J, Funk RH et al. Anti-proliferative properties of 
the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for 
treatment of obliterative bronchiolitis in heterotopic rat allografts. J Heart Lung Transplant 2001; 20: 1188-98. 
 
Rubin K, Tingstrom A, Hansson GK, Larsson E, Ronnstrand L, Klareskog L et al. Induction of B-type receptors 
for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular 
proliferative lesions. Lancet 1988; 1: 1353-6. 
 
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. 
Gastroenterology 2004; 126: 1593-610. 
 
Sack FU, Vielfort TJ, Koch A, Haass M, Taylor S, Otto HF et al. The role of platelet derived growth factor in 
endomyocardial biopsies shortly after heart transplantation in relation to postoperative course. Eur J 
Cardiothorac Surg 2004; 25: 91-7. 
 
Saiki T, Ezaki T, Ogawa M, Maeda K, Yagita H, Matsuno K. In vivo roles of donor and host dendritic cells in 
allogeneic immune response: cluster formation with host proliferating T cells. J Leukoc Biol 2001; 69: 705-12. 
 
Saito R, Prehn J, Zuo XJ, Marchevesky A, Castracane J, Waters P et al. The participation of tumor necrosis 
factor in the pathogenesis of lung allograft rejection in the rat. Transplantation 1993: 55; 967-72. 
 
Sakiyama S, Uyama T, Tanida N, Fukumoto T, Nagasawa H, Himeno K et al. Pathogenesis of late airway 
changes in long-term surviving lung allografts. Am J Respir Crit Care Med 1994; 150: 1137-41. 
 
Salmela K, Höckerstedt K, Salminen US, Hämmäinen P. Elinsiirrot – käypää hoitoa jo 40 vuoden ajan. 
Duodecim 2004; 120: 1359-69. 
 
Salminen US, Maasilta PK, Taskinen EI, Alho HS, Ikonen TS, Harjula AL. Prevention of small airway 
obliteration in a swine heterotopic lung allograft model. J Heart Lung Transplant 2000; 19: 193-206. 
 
Salminen US, Maasilta PK, Harjula AL, Romanska HM, Bishop AE, Polak JM. Nitric oxide in the development 
of obliterative bronchiolitis in a heterotopic pig model. Transplantation 2002; 73: 1724-9. 
 
Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-6.  
 
Savikko J, Kallio EA, Willebrand E. Early induction of platelet-derived growth factor ligands and receptors in 
acute rat renal allograft rejection. Transplantation 2001; 72: 31-7. 
 
Savikko J, Taskinen E, von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of PDGF 
receptor: Tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75:1147-53. 
 
Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J 
Med 1998; 338: 1813-21. 
 
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 
binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9. 
 
Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor 
necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated 
enhancement of T cell responses. J Immunol 1987; 138: 1786-90. 
 80
Schild C, Trueb B. Mechanical stress is required for high-level expression of connective tissue growth factor. 
Exp Cell Res 2002; 274: 83-91. 
 
Schmid RA, Stammberger U, Hillinger S, Gaspert A, Boasquevisque CH, Malipiero U et al. Fas ligand gene 
transfer combined with low dose cyclosporine A reduces acute lung allograft rejection. Transpl Int 2000; 13 
Suppl 1: S324-8. 
 
Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP et al. Identification of integrin 
alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue 
growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002; 99: 
4457-65. 
 
Scholma J, Slebos DJ, Boezen HM, van den Berg JW, van der Bij W, de Boer WJ et al. Eosinophilic 
granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of 
obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000; 162: 2221-5. 
 
Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ et al. SDZ RAD, a new rapamycin 
derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42. 
 
Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R et al. SDZ RAD, a new rapamycin 
derivative: synergism with cyclosporine. Transplantation 1997; 64: 32-5. 
 
Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-56. 
 
Scott JP, Wallwork J. The use of allopurinol in the inhibition of obliterative bronchiolitis of the transplanted 
lung. Transpl Int 1992; 5 Suppl 1: S246-8. 
 
Sedgwick JD, Riminton DS, Cyster JG, Körner H. Tumor necrosis factor: a master regulator of leukocyte 
movement. Immunol Today 2000; 21: 110-3. 
 
Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor 
mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473-9.  
 
Sekine Y, Bowen LK, Heidler KM, Van Rooijen N, Brown JW, Cummings OW et al. Role of passenger 
leukocytes in allograft rejection: effect of depletion of donor alveolar macrophages on the local production of 
TNF-alpha, T helper 1/T helper 2 cytokines, IgG subclasses, and pathology in a rat model of lung 
transplantation. J Immunol 1997; 159: 4084-93. 
 
Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE et al. Tissue distribution and clinical 
monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant 
recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323-32. 
 
Shahzeidi S, Mulier B, de Crombrugghe B, Jeffrey PK, McAnulty RJ, Laurent GJ. Enchanced type III collagen 
gene expression during bleomycin induced lung fibrosis. Thorax 1993; 48: 622-8.  
 
Shahzeidi S, Jeffrey PK, Laurent GJ, McAnulty RJ. Increased type I procollagen mRNA transcripts in the lungs 
of mice during the development of bleomycin-induced fibrosis. Eur Respir J 1994; 7: 1938-43. 
 
Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of 
recent publications. J Heart Lung Transplant 2002; 21: 271-81. 
 
Shaw MJ, Shennib H, Bousette N, Ohlstein EH, Giaid A. Effect of endothelin receptor antagonist on lung 
allograft apoptosis and NOSII expression. Ann Thorac Surg 2001; 72: 386-90. 
 
Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production 
via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004; 279: 23166-75. 
 
Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI et al. Transforming growth factor-beta and 
matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995; 6: 
286-94. 
 81
Shinbori T, Walczak H and Krammer PH Activated T killer cells induce apoptosis in lung epithelial cells and the 
release of pro-inflammatory cytokine TNF-alpha. Eur J Immunol 2004; 34: 1762-70. 
 
Shirwan H. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen 
recognition play a dominant role? Transplantation 1999; 68: 715-26. 
 
Sho M, Sandner SE, Najafian N, Salama AD, Dong V, Yamada A et al. New insights into the interactions 
between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236: 667-
75. 
 
Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-
8. 
 
Shreeniwas R, Schulman LL, Narasimhan M, McGregor CC, Marboe CC. Adhesion molecules (E-selectin and 
ICAM-1) in pulmonary allograft rejection. Chest 1996; 110: 1143-9. 
 
Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev 
Respir Dis 1990; 141: 471-501. 
 
Sihvola R, Koskinen P, Myllarniemi M, Loubtchenkov M, Hayry P, Buchdunger E et al. Prevention of cardiac 
allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. 
Circulation 1999; 99: 2295-301. 
 
Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O et al. Platelet-derived growth factor 
inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 2003; 
75:334-9. 
 
Sivasai KS, Smith MA, Poindexter NJ, Sundaresan SR, Trulock EP, Lynch JP et al. Indirect recognition of donor 
HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 
67: 1094-8. 
 
Slebos DJ, Scholma J, Boezen HM, Koeter GH, van der Bij W, Postma DS et al. Longitudinal profile of 
bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am J 
Respir Crit Care Med 2002; 165: 501-7. 
 
Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell 
infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. 
Arthritis Rheum 2003; 48: 2155-62. 
 
Smith CR, Jaramillo A, Lu KC, Higuchi T, Kaleem Z, Mohanakumar T. Prevention of obliterative airway 
disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. Transplantation 
2001; 72: 1512-8. 
 
Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN et al. Sirolimus allows renal recovery in 
lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540-6. 
 
Song E, Zou H, Yao Y, Proudfoot A, Antus B, Liu S et al. Early application of Met-RANTES ameliorates 
chronic allograft nephropathy. Kidney Int 2002; 61: 676-85. 
 
Squier MK, Sehnert AJ, Cohen JJ. Apoptosis in leukocytes. J Leukoc Biol 1995; 57: 2-10. 
 
Stammberger U, Gaspert A, Hillinger S, Vogt P, Odermatt B, Weder W et al. Apoptosis induced by ischemia 
and reperfusion in experimental lung transplantation. Ann Thorac Surg 2000; 69: 1532-6. 
 
Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-9. 
 82
Strieter RM, Lukacs NW, Kunkel SL. Role of adhesion molecules and cytokines in lung transplantation. In: 
Ward PA, Fantone JC, editors. Adhesion molecules and the lung. New York: Marcel Dekker, Inc; 1996, p. 279-
310. 
 
Strom TB, Roy-Chaudhury P, Manfro R, Zheng XX, Nickerson PW, Wood K et al. The Th1/Th2 paradigm and 
the allograft response. Curr Opin Immunol 1996; 8: 688-93. 
 
Sundaresan S, Alevy YG, Steward N, Tucker J, Trulock EP, Cooper JD et al. Cytokine gene transcripts for 
tumor necrosis factor-alpha, interleukin-2, and interferon-gamma in human pulmonary allografts. J Heart Lung 
Transplant 1995; 14: 512-8. 
 
Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003; 2: 346-57. 
 
Szabolcs M, Michler RE, Yang X, Aji W, Roy D, Athan E et al. Apoptosis of cardiac myocytes during cardiac 
allograft rejection. Relation to induction of nitric oxide synthase. Circulation 1996; 94: 1665-73. 
 
Taylor PM, Rose ML, Yacoub MH. Expression of MHC antigens in normal human lungs and transplanted lungs 
with obliterative bronchiolitis. Transplantation 1989; 48: 506-10.  
 
Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R et al. Reduction of chemokine levels 
and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. 
Arthritis Rheum 2000;43:38-47. 
  
Tazelaar H, Starnes V. Lung and heart-lung transplantation pathology. In: Kolbeck PC, Markin RS, McManus 
BM, editors. Transplant pathology. Chicago: American Society of Clinical Pathologist; 1994, p. 219-40. 
 
Tikkanen JM, Lemstrom KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental 
obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune 
response. Am J Respir Crit Care Med 2002; 165: 724-9. 
 
Tikkanen JM, Krebs R, Bruggeman C, Lemström KB, Koskinen PK. Platelet-derived growth factor regulates 
cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts. Transplantation 2003; 
77: 655-58. 
 
Tikkanen JM, Koskinen PK, Lemstrom KB. Role of endogenous endothelin-1 in transplant obliterative airway 
disease in the rat. Am J Transplant 2004; 4: 713-20. 
 
Tiroke AH, Bewig B, Haverich A. Bronchoalveolar lavage in lung transplantation. State of the art. Clin 
Transplant 1999; 13: 131-57. 
 
Treede H, Reichenspurner H, Meiser B, Schenk S, Kur F, Furst H et al. Influence of four different 
immunosuppressive protocols on acute and chronic rejection (BOS) after lung transplantation - experiences in 
120 patients. J Heart Lung Transplant 2001a; 20: 176. 
 
Treede H, Klepetko W, Reichenspurner H, Zuckermann A, Meiser B, Birsan T et al. Tacrolimus versus 
cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different 
immunosuppressive protocols. J Heart Lung Transplant 2001b; 20: 511-7. 
 
Trulock EP, Edwards LB, Taylor DO, Boucek MM, Mohacsi PJ, Keck BM et al. The Registry of the 
International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant 
report - 2003. J Heart Lung Transplant 2003; 22: 625-35.  
 
Trulock E, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. The Registry of the International 
Society for Heart and Lung Transplantation: Twenty first Official adult lung and heart-lung transplant report - 
2004. J Heart Lung Transplant 2004; 23: 804-15. 
 
Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft 
rejection. Transplantation 1995; 59: 313-8. 
 83
Ueland T, Sikkeland LI, Yndestad A, Eiken HG, Holm T, Guevara C et al. Myocardial gene expression of 
inflammatory cytokines after heart transplantation in relation to the development of transplant coronary artery 
disease. Am J Cardiol 2003; 92: 715-7. 
 
Ussetti P, Laporta R, de Pablo A, Carreno C, Segovia J, Pulpon L. Rapamycin in lung transplantation: 
preliminary results. Transplant Proc 2003; 35: 1974-7.  
 
Uusitalo MH, Salminen US, Ikonen TS, Taskinen EI, Lautenschlager IT, Maasilta PK et al. Alloimmune injury 
preceding airway obliteration in porcine heterotopic lung implants: a histologic and immunohistologic study. 
Transplantation 1999; 68: 970-5. 
 
Uyama T, Winter JB, Groen G, Wildevuur CR, Monden Y, Prop J. Late airway changes caused by chronic 
rejection in rat lung allografts. Transplantation 1992; 54: 809-12. 
 
Valle E, Gross M, Bickston SJ. Infliximab. Expert Opin Pharmacother 2001; 2: 1015-25. 
 
Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al. Infliximab but 
not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. 
Gastroenterology 2003; 124: 1774-85. 
 
Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis 
to tumor necrosis factor-alpha inhibition. Chest 2002; 122: 1093-6. 
 
Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB et al. Indirect 
allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with 
chronic graft dysfunction. Transplantation 1997; 64: 795-800.  
 
Venuta F, De Giacomo T, Rendina EA, Quattrucci S, Mercadante E, Cimino G et al. Recovery of chronic renal 
impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004; 78: 1940-3. 
 
Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans after lung transplantation. Curr 
Opin Organ Transplantation 2003; 8: 239-42. 
 
Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 2003; 55: 57-66. 
 
Visner GA, Lu F, Zhou H, Latham C, Agarwal A, Zander DS. Graft protective effects of heme oxygenase 1 in 
mouse tracheal transplant-related obliterative bronchiolitis. Transplantation 2003; 76: 650-6. 
 
Vitulo P, Oggionni T, Cascina A, Arbustini E, D'Armini AM, Rinaldi M et al. Efficacy of tacrolimus rescue 
therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21: 435-9. 
 
Vuorio EI, Mäkelä JK, Vuorio TK, Poole A, Wagner JC. Characterization of excessive collagen production 
during development of pulmonary fibrosis induced by chronic silica inhalation in rats. Br J Exp Path 1989; 70: 
305-15. 
 
Wallace AH, Bellamy COC, Rassl DM, Harrison DJ. Transplant histopathology for the general histopathologist. 
Histopathology 2003; 43: 313-22.  
 
Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 
8628-33. 
 
Ward C, Whitford H, Snell G, Bao H, Zheng L, Reid D et al. Bronchoalveolar lavage macrophage and 
lymphocyte phenotypes in lung transplant recipients. J Heart Lung Transplant 2001; 20: 1064-74. 
 
Wershil BK, Murakami T, Galli SJ. Mast cell-dependent amplification of an immunologically nonspecific 
inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced 
by phorbol 12-myristate 13-acetate. J Immunol 1988; 140: 2356-60. 
 
Whitehead BF, Stoehr C, Finkle C, Patterson G, Theodore J, Clayberger C et al. Analysis of bronchoalveolar 
lavage from human lung transplant recipients by flow cytometry. Respir Med 1995; 89: 27-34. 
 84
Wiedmeier SE, Mu HH, Araneo BA, Daynes RA. Age- and microenvironment-associated influences by platelet-
derived growth factor on T cell function. J Immunol 1994; 152: 3417-26. 
 
Workalemahu G, Foerster M, Kroegel C, Braun RK. Human gamma delta-T lymphocytes express and synthesize 
connective tissue growth factor: effect of IL-15 and TGF-beta 1 and comparison with alpha beta-T lymphocytes. 
J Immunol 2003; 170: 153-7. 
 
Xie S, Sukkar MB, Issa R, Oltmanns U, Nicholson A, Chung KF. Regulation of TGF-β1-induced connective 
tissue growth factor (CTGF) expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 
2005; 288: L68-76. 
 
Yagyu K, van Breda Vriesman PJ. Apoptosis in bronchiolitis obliterans, chronic rejection and infection after 
lung transplantation in rats. Transplant Proc 1997; 29: 1532-5. 
 
Yamada T, Zhu D, Saxon A, Zhang K. CD45 controls interleukin-4-mediated IgE class switch recombination in 
human B cells through its function as a Janus kinase phosphatase. J Biol Chem 2002; 277: 28830-5. 
 
Yamashita H, Akamine S, Sumida Y, Inoue M, Sawada T, Nagayasu T et al. Inhaled nitric oxide attenuates 
apoptosis in ischemia-reperfusion injury of the rabbit lung. Ann Thorac Surg 2004; 78: 292-7. 
 
Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T 
lymphocyte responses. Annu Rev Immunol 1999; 17: 51-88. 
 
Yousem SA, Paradis IL, Dauber JA, Zeevi A, Rabinowich H, Duquesnoy R et al. Large airway inflammation in 
heart-lung transplant recipients - its significance and prognostic implications. Transplantation 1990; 49: 654-6. 
 
Yousem SA, Suncan SR, Ohori P, Somnez-Alpan E. Architectural remodeling of lung allografts in acute and 
chronic rejection. Arch Pathol Lab Med 1992; 116: 1175-80. 
 
Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH et al. Revision of the 1990 working 
formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung 
Transplant 1996; 15: 1-15. 
 
Yousem SA. The potential role of mast cells in lung allograft rejection. Hum Pathol 1997; 28: 179-82. 
 
Zavazava N, Kabelitz D. Alloreactivity and apoptosis in graft rejection and transplantation tolerance. J Leukoc 
Biol 2000; 68: 167-74. 
 
Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M et al. Downregulation of epithelial apoptosis 
and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004; 53: 
1295-302. 
 
Zhang K, Gharaee-Kermani M, McGarry B, Phan SH. In situ hybridization analysis of rat lung α1(I) and α2(I) 
collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection. Lab Invest 1994; 
70: 192-202. 
 
Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine 
networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997; 158: 954-9. 
 
Zheng L, Ward C, Snell GI, Orsida BE, Li X, Wilson JW et al. Scar collagen deposition in the airways of 
allografts of lung transplant recipients. Am J Respir Crit Care Med 1999; 155: 2072-7. 
 
Zheng L, Walters EH, Ward C, Wang N, Orsida B, Whitford H et al. Airway neutrophilia in stable and 
bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 2000; 55: 53-9. 
 85
